

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number
WO 02/46444 A2

(51) International Patent Classification⁷: **C12N 15/90**

(21) International Application Number: PCT/US01/46311

(22) International Filing Date: 5 December 2001 (05.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/251,482 5 December 2000 (05.12.2000) US

(71) Applicant: **WISCONSIN ALUMNI RESEARCH FOUNDATION** [US/US]; 614 North Walnut Street, P.O. Box 7365, Madison, WI 53707-7365 (US).

(72) Inventors: **GORYSHIN, Igor, Yu**; Apt. D, 23 University Houses, Madison, WI 53705 (US). **NAUMANN, Todd, A.**; 2233 Concord Drive, State College, PA 16801 (US). **REZNIKOFF, William, S.**; 733 Lakewood Boulevard, Madison, WI 53705 (US).

(74) Agent: **BERSON, Bennett, J.**; Quarles & Brady LLP, P.O. Box 2113, Madison, WI 53701-2113 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DOUBLE TRANSPOSITION METHODS FOR MANIPULATING NUCLEIC ACIDS

(57) Abstract: Methods are provided for manipulating nucleic acid to produce gene fusions, to delete or clone a portion of a chromosome, or to insert a sequence into a chromosome. The methods employ sequential transposition processes using two or more pairs of inverted repeat transposase-interacting sequences on a transposable polynucleotide wherein each pair of transposase-interacting sequences interacts with a distinct transposase enzyme.



WO 02/46444 A2

DOUBLE TRANSPOSITION METHODS FOR MANIPULATING NUCLEIC ACIDS

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of US Provisional Patent application number 60/251,482, filed December 5, 2000, which application is incorporated by reference herein as if set forth in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
OR DEVELOPMENT

[0002] This invention was made with United States government support awarded by the National Institutes of Health, Grant No. GM50692. The United States has certain rights in this invention.

BACKGROUND OF THE INVENTION

[0003] Manipulation of nucleic acids and proteins is an important aspect of modern molecular biology. In particular, the science of combinatorial genetics has advanced in recent years as it has become apparent that proteins having altered structure and function can be engineered by swapping large or small portions of the amino acid sequence with other related or unrelated amino acid sequences. Using this approach, it is also possible to engineer novel proteins that bring together in a single molecule the structures and functions of diverse molecules. Such manipulations are most readily undertaken at the nucleic acid level. The nucleic acids thus produced can be transcribed to produce fusion RNAs and translated either *in vitro* or *in vivo* using known methods and the recombinant proteins thus produced can be isolated. Other manipulations, such as inserting polynucleotides of interest into a chromosome, deleting sections of a chromosome, or cloning sections of a chromosome are also of interest. Moreover, various approaches are known for shuffling gene pieces and selecting or screening for products having one or more desired activities or properties. Examples of such technologies include US Patent Numbers 5,605,793, 5,830,721, and 6,132,970. A number of companies including Maxygen, Diversa, Applied Molecular Evolution, and Genencor International among others specialize in directed molecular evolution. See Pollack, A., "Selling Evolution in Ways Darwin Never Imagined," New York Times, page B1, October 28, 2000.

[0004] Recently, non-transposition based methods for generating large libraries of randomly fused genes have been reported. Ostermeir and co-workers first described a method

termed ITCHY that involves the incremental truncation of two genes by use of ExoIII nuclease followed by S1 nuclease treatment, polymerization, and ligation of fragments to form random fusions (Ostermeier *et al.*, 1999; Lutz *et al.*, 2000). A second method has also been reported that utilizes random cleavage of DNA followed by a series of digestion and ligation reactions to create random fusions. This technique, called SHIPREC, also has features that increase the amount of useful fusions if both proteins have similar length and domain organization (Seiber *et al.*, 2001). Existing methods for gene shuffling and chromosome manipulation are complex and can exhibit a bias for or against particular recombination sites and sequences. Thus, the art continues to develop more sophisticated manipulations.

[0005] Various aspects of an *in vitro* transposition system that employs sequences from, and sequences derived from, the Tn5 transposon are described in US Patent Numbers 5,925,545, 5,948,622, and 5,965,443, each of which is incorporated by reference herein as if set forth in its entirety. International publication Number WO 00/17343, also incorporated herein by reference as if set forth herein in its entirety, discloses a system for introducing into cells synaptic complexes that comprise a Tn5 transposase and a polynucleotide having flanking sequences that operably interact with the transposase to form a synaptic complex.

[0006] Even though these known systems for Tn5-based *in vitro* transposition are effective and very useful, they do not provide sufficient manipulative control to meet the technological goals noted above.

[0007] Efforts are also underway to define so-called minimal bacterial genomes for growth under defined conditions and, similarly, to identify genes essential for growth under defined conditions. Determining the content required for a minimal bacterial genome is of intense interest. One approach is to assemble the theoretical minimal genome *in silico* by comparing a variety of different microbial genomes. Alternatively, the smallest genome amongst existing genomes (mycoplasma) can be analyzed by mutagenesis. *E. coli* K12 is a preferred bacterium, because of its simplicity in handling, and its short generation time. It is desirable to try to generate a minimal or significantly reduced *E. coli* K12 genome, which may shorten the already short doubling time in rich media.

[0008] Recently developed transposon-based approaches involve inserting a transposon into a gene to (1) knockout or disrupt a gene function or (2) introduce a lethal mutation that cannot be observed in an essential gene. These methods essentially catalogue transposition into non-essential genes. It is assumed that any gene that contains no transposon insert is essential.

[0009] An important alternative approach involves affirmatively identifying essential genes in libraries of cells, where the cells contain transposons having selectively regulated outwardly-facing promoters inserted upstream from an essential gene. While the cells of interest are not viable on media that cannot activate a transposon promoter, expression is restored by selectively activating either or both of the transposon promoters. Unfortunately, only a few of the transposon inserts in a library will insert into the promoter region of an essential gene.

BRIEF SUMMARY OF THE INVENTION

[0010] In a first aspect, the invention is summarized in that a transposable polynucleotide is suitable for use in methods for manipulating nucleic acids to create libraries of cells that contain transposed nucleic acid when the polynucleotide comprises two or more inverted repeat sequence pairs (“transposase-interacting sequences”) arranged as disclosed herein, where each pair has a distinct and separable ability to interact with a distinct transposase enzyme. The pairs can be provided in a nested fashion such that both members of one pair are flanked by both members of the second pair. In a related aspect, it is not essential to provide two complete pairs of transposase-interacting sequences in a single transposon, nor to introduce all of the transposase-interacting sequences by transposition. Rather, as will become more apparent below, a first member of one pair can separately be provided directly on the substrate DNA for use in a second of two transposition events with a second member of the pair, the second member being introduced during a first of two transposition events. By providing and arranging selectable markers, origins of replication, and/or other nucleotide sequences of interest on the transposable polynucleotide, one can direct sequential transposition processes to achieve the desired manipulated nucleic acids.

[0011] In a related aspect, the invention is a transposable polynucleotide having transposase-interacting sequences and additional sequences arranged as disclosed elsewhere herein. The nature of the arrangement dictates the uses to which the transposable polynucleotides can be put.

[0012] In yet another aspect, the invention is summarized in that the transposable polynucleotides are introduced into host cells as disclosed to produce libraries of cells that achieve the objects of the invention. Using selection and screening methods, cells that have undergone desired transpositions can be obtained. In certain embodiments, the host cells transcribe and translate double transposition products produced entirely *in vitro*. In other embodiments, a synaptic complex formed *in vitro* between a first transposase and a transposable

polynucleotide of the invention is introduced into a host cell whereupon the transposable polynucleotide is transposed into the host cell chromosome. This first transposition is followed, upon induction of a second transposase, by a second round of transposition *in vivo* to yield chromosomal insertions or deletions or cloned products excised from the host cell chromosome.

[0013] In another aspect, the invention is summarized in that a host cell contains an extrachromosomal circular polynucleotide that comprises first and second polynucleotide fusion portions, each polynucleotide fusion portion comprising a pair of segments from a pair of sequences that can encode a fusion RNA that can be translated to produce a fusion polypeptide, the members of the pair flanking a pair of transposase-interacting sequences each having a distinct and separable ability to interact with one of a pair of transposase enzymes, the pair of transposase-interacting sequences defining a junction between the two segments. In certain embodiments, the junction has a nucleic acid sequence that permits transcription and translation of both fusion segments across the junction.

[0014] In yet another aspect, the present invention is summarized in that a host cell contains a chromosome deleted in length relative to a wild type chromosome and comprising at the deletion site in place of the excised material, a pair of transposase-interacting sequences each having a distinct and separable ability to interact with one of a pair of transposase enzymes. In certain embodiments, the host cell further contains a self-replicating nucleic acid molecule that itself comprises the deleted portion of the host cell chromosome. In other embodiments, the host cell chromosome further comprises at the deletion site a segment of pre-selected nucleic acid between the pair of transposase-interacting sequences.

[0015] Still another aspect of the invention is summarized in that the transposase-interacting sequences are inverted repeats provided in inverted pairs on the polynucleotide for transposition. The two kinds of transposase-interacting sequences can be separate from one another, can be abutted end to end, or can overlap when it is particularly desirable to minimize the size of such sequence elements. As is detailed below, the transposase-interacting sequences can be engineered to ensure an open reading frame in either or both polarity, as desired.

[0016] It is an object of the invention to provide a system for manipulating nucleic acids *in vitro* and *in vivo*.

[0017] It is another object of the invention to generate a library of random fusions between two polynucleotide or polypeptide sequences, preferably between sequences that, respectively, encode and define peptides or proteins of interest.

[0018] It is a feature of the invention that the system employs two pairs of transposase-interacting sequences each interacting with a distinct transposase.

[0019] It is an advantage of the invention that transpositions occur without regard to the sequences of the nucleic acids into which the transposable elements transpose.

[0020] It is another advantage of the invention that large libraries (e.g., $>10^7$ individuals) having a high level of variability can be produced.

[0021] Other objects, features and advantages will become apparent upon consideration of the following detailed description taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

[0022] Fig. 1 depicts a pair of preferred arrangements of full-length and interleaved (compressed) transposase-binding sequences that face in opposite directions.

[0023] Fig. 2 depicts a first approach to a method for producing a gene fusion library for obtaining directed gene and protein evolution products. In the first approach, a first transposase binds to and interacts with first transposase-interacting sequences in a donor polynucleotide (shown schematically as black triangles) whereupon the newly created transposon is transposed into a first target nucleic acid molecule that contains an appropriately-oriented transposase-interacting sequence to yield a set of first transposition products. Then, a second transposase binds to and interacts with the second transposase-interacting sequences, now both resident in the members of the set of first transposition products (shown schematically as white triangles), whereupon the donor portions of the first products are transposed into a second target nucleic acid molecule. The resulting nucleic acid molecule comprises a fusion sequence having a junction portion that includes a pair of distinct transposase-interacting sequences. It will be understood that only a few exemplary transposition products are shown, but that, in fact, the library of transposition products produced reflects the combinatorial variety resulting from the sequential transposition processes.

[0024] Fig. 3 depicts a second approach to a method for producing a gene fusion library for obtaining directed gene and protein evolution products. In the second approach, a first transposase binds to and interacts with first transposase-interacting sequences in a donor polynucleotide (shown schematically as black triangles) whereupon the newly created transposon is transposed into a first target nucleic acid molecule to yield a set of first transposition products. Then, a second transposase binds to and interacts with the second transposase-interacting sequences in the first transposition products (shown schematically as white triangles) whereupon

the donor portions of the first products are transposed into a second target nucleic acid molecule. The resulting nucleic acid molecule comprises a pair of fusion sequences, each fusion sequence having a junction portion that includes a pair of distinct transposase-interacting sequences. Again, it will be understood that only a few exemplary transposition products are shown, but that, in fact, the library of transposition products produced reflect the combinatorial variety resulting from the sequential transposition processes.

[0025] Fig. 4 depicts a first aspect of a construct and method for inserting the construct into a chromosome of bacterial host cell using the method for incorporating a synaptic complex between a transposase enzyme and donor DNA into a host cell chromosome as disclosed in incorporated International patent Application No. WO 00/17343. Other constructs described below can also be inserted into a bacterial host cell chromosome using this same first aspect.

[0026] Fig. 5 depicts intrachromosomal *in vivo* transposition of a construct introduced into the bacterial chromosome as generally shown and described in Fig. 4. This *in vivo* transposition yields a deleted chromosome carrying a small residual mismatched pair of transposase binding sequences. A second circular product carries a segment of deleted chromosomal material that cannot replicate because it lacks a bacterial origin of replication.

[0027] Fig. 6 depicts a screen for deletion products following the double transposition method of Figs. 4 and 5.

[0028] Fig. 7 depicts intrachromosomal *in vivo* transposition of a construct introduced into the bacterial chromosome as generally shown and described in Fig. 4. By including an origin of replication in this construct, the deleted chromosomal material (as in Fig. 5) can be maintained, amplified, and isolated for further use or study.

[0029] Fig. 8 depicts an intrachromosomal *in vivo* transposition of a construct introduced into the bacterial chromosome as generally shown and described in Fig. 4. By including in this construct a desired insert, between a mismatched pair of transposase binding sequences, the resulting bacterial chromosome includes the insert at the site of the chromosomal deletion that yields a desired insert added into the bacterial chromosome at the site of the first transposition event.

[0030] Fig. 9 depicts suitable transposons Tn5DEL7 and Tn5DEL8 for forming, respectively, deletions in a bacterial chromosome, and deletions in a bacterial chromosome while capturing the deleted portions in an extrachromosomal plasmid.

[0031] Fig. 10 depicts a set of bacterial chromosomal deletions induced in a method according to the invention.

DETAILED DESCRIPTION OF THE INVENTION

[0032] Mutant Tn5 transposase enzymes can preferentially bind to and interact with distinct inverted repeat sequences. The end preference of a mutant transposase can be characterized either (1) by the *in vivo* transposition frequency observed when it is used in a system in which the target polynucleotide is flanked with particular termini, or (2) by the ratio of the *in vivo* transposition frequencies observed when it is used in a pair of systems in which the target polynucleotide is flanked with the termini, respectively. *In vitro* transposition frequency characterization is also possible.

[0033] The constructs and methods of the invention all employ two pairs of inverted repeat sequences ("transposase-interacting sequences") that bind to and interact with a pair of transposase enzymes to facilitate directed double transposition as detailed below. The transposases are referred to generally herein as transposase 1(Tnp1) and transposase 2(Tnp2). There are no preordained requirements for the transposase-interacting sequences except that the combination of Tnp1 and the sequences that preferentially bind to and interact with it have a distinct and separable activity from the combination of Tnp2 and its preferential binding sequences.

[0034] By way of example, the Tn5 transposon includes inside end sequences (IE) and outside end sequences (OE). A transposase that preferentially binds to and interacts with OE, but not IE, is known and disclosed in incorporated US Patent Number 5,965,443. The hyperactive transposase there disclosed includes a mutation at position 54 and a mutation at position 372 that confer upon the Tn5 transposase a greater avidity for Tn5 outside end repeat sequences than wild type Tn5 transposase. A preferred embodiment of that transposase includes a lysine at position 54 and a proline at position 372. A most preferred embodiment of that transposase also includes an alanine residue at position 56. The preferred transposase of US 5,965,443 is referred to as Tnp EK/LP. All embodiments of the transposase disclosed in the incorporated patent are useful in the present invention. In the examples that follow, this transposase is represented as Tnp2.

[0035] Further incorporated US Patent No. 5,925,545 discloses that a TnpEK/LP-transposase-catalyzed *in vitro* transposition frequency at least as high as that of wild type OE is achieved if the termini include bases ATA at positions 10, 11, and 12, respectively, as well as the nucleotides in common between wild type OE and IE (e.g., at positions 1-3, 5-9, 13, 14, 16, and optionally 19). The nucleotides at positions 4, 15, 17, and 18 can correspond to the nucleotides found at those positions in either wild type OE or wild type IE. It is noted that the transposition

frequency can be further enhanced over that of wild type OE if the nucleotide at position 4 is a T. The so-called "mosaic end sequences" ("ME") of US Patent No. 5,925,545 can be advantageously used in the present invention instead of wild-type OE sequences. Where "ME" sequences are used in the patent application, it is understood that ME and wild type OE sequences can be used, although use of ME yields a higher transposition frequency. Accordingly, Tnp2 can also be referred to as Tnp-OE or Tnp-ME. It is noted that, in the presence of Tnp EK/LP (Tnp2), a transposon having one ME and one OE transposes at higher frequency than one having a pair of OE termini. Transposons having ME-ME termini seem to transpose at a still slightly higher frequency.

[0036] On the other hand, a second class of hyperactive Tn5 transposase mutants exhibits a dramatic preference for Tn5 inside end sequences, and in some cases, methylated inside ends (IE^{ME}), rather than for outside ends (OE), which are unmethylated because they lack a methylation site. The members of this class of Tn5 transposase mutants differ from wild-type Tn5 transposase protein at least at amino acid position 58 or position 372. In a preferred version, the second hyperactive Tn5 transposase mutant differs from wild-type in that it includes a cysteine at amino acid position 8, a valine at amino acid position 58, a lysine at amino acid position 344, and a glutamine at amino acid position 372. This transposase having four differences from wild type Tn5 transposase is referred to as Tnp sC7v2.0 and is used in the examples that follow, where it is represented as Tnp1 or Tnp-IE.

[0037] The aforementioned transposase enzymes having distinct and separable abilities to interact with distinct transposase-interacting sequences are preferred transposases for use in the methods of the invention. However, as long as one coordinates the relative positions of the transposase-interacting sequence pairs with the sequence (order) of providing the appropriate transposase, there is no requirement that either one of the transposases corresponds to transposase Tnp1 or Tnp2 as shown in the Figures. It is advantageous that the transposase enzymes have a hyperactive transposition efficiency relative to wild-type Tn5 transposase. Particularly when screening for transposition events, it is desirable for every cell to have undergone a transposition event. Accordingly, as a guideline, at least a 1000 fold activity increase relative to wild-type Tn5 transposase is considered to be preferred. The Tnp sC7v2.0 IE-specific enzyme described above is about 1000 fold more active than wild-type Tn5 transposase. The Tnp EK/LP is at least again about 10-100 fold more hyperactive than Tnp sC7v2.0. Mutant derivatives of these enzymes having still higher transposition activities while retaining their indicated specificities would be advantageously employed in the methods.

[0038] One can practice the method by providing the pairs of transposase-interacting sequences on a transposon in a nested manner such that the outer pair is employed to introduce the transposon into a target DNA. As an alternative, one member of a first pair of transposase-interacting sequences can be provided on the target while the second is provided in a proper orientation on the transposon, flanked by the second pair. When the transposon is subsequently introduced into the target, the first and second members of the first pair of transposase-interacting sequences are then positioned for subsequent transposition in the presence of a suitable transposase enzyme.

[0039] It is also possible, but less preferred, to practice the methods of the invention using a single transposase enzyme with pairs of the corresponding end sequence arranged in inverted back-to-back positions. In this approach, one can rely upon the screening and selection methods to yield only the transposition products of interest. However, the method is less preferred because it cedes some measure of control over the transposition processes themselves.

[0040] The methods of the invention are described below and are conceptually related in that each takes advantage first of one transposase/end sequence set to accomplish a first transposition event and then, second, of a second transposase/end sequence set to accomplish the second transposition event. By carefully engineering the placement of various components on the transposable element in each case, one can produce fusion RNAs, fusion proteins, chromosomal deletions, chromosomal insertions, or cloned chromosomal segments. The precise structures of the pairs of transposase-interacting sequences are described below. At this juncture, it is important only to note when considering the following disclosure, that, in this application, Tnp1 preferentially binds to and interacts with the end sequences shown schematically as black triangles while Tnp2 preferentially binds to and interacts with the end sequences shown as white triangles. The triangle points signify the inverted orientations of the members of each pair.

[0041] In the methods of the present invention, Tnp1 and Tnp2 are separately and sequentially provided to donor and target DNA molecules to promote directed evolution by two sequential transposition events. The result of the various methods disclosed depends upon the components provided on the transposed polynucleotides. Conceptually, it makes no difference whether Tnp1 or Tnp2 is used first, as long as the ends are provided in an orientation that directs the two transposition events to occur in the desired order.

[0042] There is some flexibility permitted in designing the sequences of the transposase-interacting sequences without appreciably reducing the OE- (or ME-) or IE-specific binding of the transposases. The incorporated US patents describe which bases of the end sequences can be

altered without unacceptably reducing the hyperactivity of the appropriate transposase. The ability to modify the end sequences can be advantageously exploited to produce a linker, such as the linker shown as compressed Linker A in Fig. 1, wherein the OE-related sequence (OE') and the IE-related sequence (IE') overlap with one another in a linker that is shorter than would be achieved by abutting the OE and IE sequences to one another. Linker A was designed by combining the IE and OE sequences. The overlap region does not match exactly the sequence of either IE or OE, hence the designations IE' and OE'. The 19 base pairs read from the top left are the IE sequence with position 18 changed from C to G (IE'). The 19 base pairs read from the bottom right match the OE sequence with positions 17 and 18 (linker positions 16 and 15) changed from AG to TC (OE'). As an alternative, compressed Linker B in Fig. 1 depicts a similar overlapped dual function linker engineered to respond to IE and ME, the mosaic ends mentioned above. Compressed Linker B differs from compressed Linker A only at position 29, as shown.

[0043] The full-length version of an IE/OE linker of Fig. 1 is accorded SEQ ID NO:1. The compressed version of an IE/OE linker of Fig. 1 (Linker A) is accorded SEQ ID NO:2. The full-length version of an IE/ME linker of Fig. 1 is accorded SEQ ID NO:3. The compressed version of an IE/ME linker of Fig. 1 (Linker B) is accorded SEQ ID NO:4.

[0044] The ability to translate gene B - gene A and gene A - gene B fusion proteins depends upon the presence in the linker region of an open reading frame in one or both directions. By carefully designing the linkers, one can allow both fusion products to be translated from start to finish or can ensure that only one fusion orientation is functional. The linkers can also be engineered to ensure that at least one reading frame is free of stop codons. This attribute ensures that combinatorial fusion proteins are translated through the transposition site. It may be preferable to design the linker so that only one reading frame is open so that all functional fusions have the same amino acids inserted at the transposition junction. It is also possible to recover functional fusion proteins in the method by altering either or both of the gene A and gene B starting target sequences such that no functional protein can be produced without two sequential transposition events, as described.

[0045] When producing gene fusion products according to the invention, the length of the linker is also important. If the length of the linker is a multiple of three and the linker contains only one open reading frame, the fusion point between the protein segments will have a constant amino acid sequence. A second consideration concerns the number of inserted amino acids resulting from the linker. It can be desirable to minimize the disruption to the natural proteins by

using as short a linker as possible. However, this can present challenges because it is difficult to overlap the linkers without introducing changes to the OE (or ME) and IE sequences that are detrimental to transposition frequency. The compressed linkers of Fig. 1 are likely to be the shortest possible linkers that employ these binding sequences. As noted above, Linker A has an IE end and an OE end; Linker B has an IE end and an ME end (see Fig. 1).

[0046] If no overlap is provided in the linker (and none is required in this or any disclosed embodiment), a thirty-nine nucleotide long linker would include a complete OE (or ME) sequence, a complete IE sequence, and a single nucleotide therebetween to bring the length of the linker to a multiple of three. These considerations are of no concern when using the invention for manipulations other than gene fusions. Indeed, in the subsequent embodiments, the linkers can be overlapping, abutted or non-overlapping unless another aspect of the method dictates a separation between mismatched transposase-interacting sequences.

[0047] It is instructive to look first at the simplest embodiments of the invention, namely processes for generating libraries of nucleic acid molecules such as plasmids that contain a pair of fused genes that can encode chimeric proteins as shown in Figs. 2 and 3. A pair of distinct protein-encoding (or partial protein-encoding) sequences (Gene A and Gene B) are provided on separate molecules. A goal of these methods for forming fusion proteins is to bring together N-terminal portions of one protein-encoding sequence with C-terminal portions of a second protein-encoding sequence, where the library of resulting fusions includes a random set of junction points. The gene portions can be from unrelated or related genes. This can be accomplished in either of two approaches that share a single underlying principle, although the constructs employed differ slightly, as is discussed below. Also, the construct that contains sequences encoding the C-terminal portion of the fusion can optionally further comprise another polynucleotide fused to the sequence that encodes the C-terminus, where the additional polynucleotide encodes a protein that can be directly selected for. This technique not only selects expressed fusion proteins for screening, but also eliminates translated fusions that result in proteins that are poorly expressed or have low solubility (Maxwell *et al.*, 1999). The successful use of a CAT gene for selecting non-homologous gene fusions has previously been reported. (Sieber *et al.*, 2001).

[0048] In one approach, depicted in Fig. 2, a transposon that confers resistance to selectable marker SMI is transposed into a first gene using Tnp1 to produce an initial insert library. Using Tnp2, the products of that library are transposed into a second gene to form fusion proteins. More particularly, each of a pair of genes A and B is provided on a separate construct

that also comprises an origin of replication and distinct selectable markers, SM2 and SM3, respectively. Gene A contributes its N-terminal portion, and Gene B contributes its C-terminal portion, to the fusion protein. In this approach, the construct that contains Gene A also includes a single Tnp2 transposase-interacting sequence upstream of the gene's promoter.

[0049] The aforementioned Gene A construct is then mixed with a pre-cleaved transposon that includes yet another distinct selectable marker (SM1) flanked at a first end by a first Tnp1-specific transposase-interacting sequence, and at a second end by a transposase-interacting sequence pair having a Tnp2-specific sequence and a second Tnp1-specific sequence, where the Tnp2-specific sequence is between the selective marker and the second Tnp1-specific sequence. In a first transposition reaction between these two nucleic acid molecules in the presence of an amount of Tnp1 effective to catalyze transposition, the transposon inserts into the target construct at random positions, some of which are in Gene A. Reaction products are then transformed into suitable host cells, such as *E. coli* cells, under standard transformation conditions. Electroporation is a suitable transformation method. The transformed cells are grown under selective pressure (SM1 and SM2) for cells that contain constructs having the Gene A construct and an integrated transposon. The resulting selected cells constitute the initial library of random linker inserts.

[0050] In the presence of an amount of Tnp2 effective to catalyze transposition, DNA from the initial insert library serves in a second transposition reaction as the transposon donor. The initial insert library DNA is mixed with the target Gene B construct and incubated until transposons are cleaved from the initial insert library and then inserted at random locations into the target construct to create the library of random fusion constructs that can encode random fusion proteins having an N-terminal end contributed by Gene A and a C-terminal end contributed by Gene B. The products are transformed into suitable host cells and selected for SM3 and against SM1 and SM2, which indicates the presence of Gene B construct without the Gene A construct or the original transposon of the first reaction. It should be noted that the Tnp2-interacting sequence in half of all inserts in the resulting initial insert library is inverted. Such inserts cannot participate in the second transposition reaction.

[0051] As mentioned above, one can alternatively introduce the transposase-interacting sequences entirely by transposition, instead of providing a single Tnp2-interacting sequence on the Gene A construct. In this second approach, two fusions are created. This second approach also employs a pre-cleaved transposon and separate Gene A and Gene B constructs. Neither of the two constructs contains transposase binding sequences at the start of the method, although

one of the two constructs contains a conditional origin of replication to prevent improper replication of the dual-origin fusion construct that is formed in the method by joining the two starting constructs. Since some fusion constructs can have two origins, improper replication could result if both starting constructs contain non-conditional origins of replication.

[0052] Fig. 3 depicts this second approach. In contrast to the first approach, the orientation of insertion is not important, as the double ends exist on both ends of the transposon. In the first transposition step, parts of genes A and B are transposed to yield a library containing two classes of fusion products, namely (1) the N-terminal end of Gene A fused to the C-terminal end of Gene B and (2) the N-terminal end of Gene B fused to the C-terminal end of Gene A, which can be transcribed and translated to produce fusion RNAs and fusion proteins.

[0053] To carry out the first transposition step in this second approach, a pre-cut transposon encoding selectable marker SM1 flanked by pairs of transposase-interacting sequences as shown and described is combined with a replication competent circular nucleic acid molecule that contains an origin of replication (which can be a conditional origin of replication such as a π -dependent ori) and a selectable marker as well as a gene sequence (Gene A) that can encode a protein. Gene A should include a transcriptional promoter upstream of the gene and a stop codon at the end of the coding sequence. The two are combined in the presence of a first transposase (Tnp1) that preferentially binds to and interacts with the pair of transposase-interacting sequences shown in black under conditions that promote *in vitro* transposition.

[0054] Plasmids in the library of *in vitro* transposition reaction products can be introduced into host cells by electroporation and cells that contain a plasmid having a transposon insertion in the protein-encoding gene of interest are obtained by plating the host cells on a medium that selects for resistance to SM1 and SM2. The selection method ensures that no member of the library has received an insertion in either the origin of replication or the selectable marker provided on the plasmid. A short linker segment remains at each fusion junction. The junction point at which the coding sequence of the first protein ends is randomly determined by this first *in vitro* transposition (strand transfer) reaction. These libraries typically contain a sufficient number of independent survivals ($>10^5$) to encompass all possible insertion sites, as determined by plating of a small dilution of the transformation mixture onto agar plates in the presence of both drugs.

[0055] In a second *in vitro* transposition reaction shown in Fig. 3, DNA from the members of the initial library are mixed *in vitro* under conditions that favor *in vitro* transposition with a second plasmid containing an origin of replication, a third selectable marker SM3, and a second

gene of interest (gene B optionally with promoter) which is intended to be fused with gene A. The origin of replication can be a conditional origin of replication if the origin of replication used in the first step was not a conditional origin. In this second round of *in vitro* transposition, plasmids from the first transposition library and the second plasmid are mixed under suitable conditions with the second transposase (Tnp2) which binds to and interacts with the pair of inverted repeats shown in white. In the resulting *in vitro* transposition, the selectable marker present on the original transposon is lost, as it forms the donor backbone DNA, and the remainder of the library plasmids are the transposable portions transposed into plasmid B. After transformation into a suitable host, those colonies that grow in the presence of SM2 and SM3 contain fusions as shown at the bottom of Fig. 3. The resulting reactions products can be directly transformed into suitable host cells and grown in mixed liquid culture under double drug selection to generate a library of desirable products. Plating of small aliquots from reactions has revealed that the library can contain $>10^7$ independent gene fusions. Alternatively, the reaction products can be subjected to selection of functional fusion products. These fusion polynucleotides can encode fusion RNAs that can be translated to produce fusion polypeptides (also referred to interchangeably herein as proteins). The total size of an individual chimeric protein can vary from zero to the total length of both proteins plus the linker segment. One can analyze the nucleic acid members of a fusion library thus created using standard cleavage and sizing methods to demonstrate the presence of fusion products.

[0056] This fusion method can be accomplished with no intermediate transfer into a host cell by relying on a single selection after the second transposition process, although this approach is disfavored because of reduced efficiency and, consequently, reduced library size. Because the transposition products in the first stage do not represent a large percentage of the total DNA, it is instead advantageous to purify the initial products so that the ratio of reactants in the second stage can be controlled to promote efficient formation of the desired products.

[0057] It is noted that many microbial selection techniques are known, including without limitation the use of selectable markers and biosynthetic and auxotrophic selections, and any such technique can be employed in the method. Selectable markers are employed in the exemplified embodiments because they are convenient and easily manipulated. A skilled artisan will understand that the selectable marker resistance gene chosen for use at any stage of the methods is not critical and all that is required is that the selection technique be appropriate for the chosen resistance gene. By way of non-limiting example, the marker can confer resistance to kanamycin, chloramphenicol, ampicillin, tetracycline or other drugs.

[0058] When manipulating the nucleic acid and cells as described herein, commercially available *E. coli* K-12 DH5 cells (recA) or JM109 cells are suitable, if no conditional origin of replication is in use. In the latter case, cells that supply the protein required for conditional replication (such as TransforMax EC100D *pir*-116 electrocompetent *E. coli* K12 cells, commercially available from Epicentre, Madison, WI) are suitable. For deletion methods any bacterial strain that supports Tn5 transposition, preferably an *E. coli* strain such as MG1655 (ATCC 47076), can be used.

[0059] The number of actual transpositional protein fusions is limited both because the correct reading frame is maintained in only 1 of 3 events and also because the transposition insert is oriented properly in only 1 of 2 events in the second reaction. Therefore, a maximum of 1 out of 6 (16.7%) of all transpositional fusions can be true protein fusions. Although this limitation on the number of productive fusion products can be ignored when the library is large, as here, it may be otherwise desirable to screen for functionally productive fusions.

[0060] The percentage of functional fusion products is further limited both by stop codons in the linker and by non-essential DNA other than the gene of interest in the construct. The former can be overcome or reduced as needed by modifying the linker sequence as appropriate to eliminate stop codons. While certain such changes could alter or even destroy the transposition reaction efficiency, it is likely that not every change that removed a stop codon would also affect transposition efficiency. The latter can be overcome by careful engineering constructs to ensure that only inserts into the gene of interest can produce productive transposition products that can both replicate and encode proper drug resistance.

[0061] Essentially the same principles apply in the additional methods disclosed below. However, each of the following methods employ as a first step the synaptic complex formation and electroporation method disclosed in incorporated International Patent Application Number WO/00/7343. Briefly, as shown in Fig. 4 a pre-cut transposon containing two pairs of transposase-interacting sequences arranged as disclosed in Fig. 4 is incubated with Tnp1 that binds to and interacts with the pair of black transposase-interacting sequences in the absence of magnesium. The initial incubation step forms a synaptic complex poised for a first transposition event in the presence of a target DNA. Upon introducing the synaptic complex into cells by, e.g., electroporation, the synaptic complex transposes into the bacterial chromosome. After introduction into the host cells, those cells that have incorporated the transposon into their chromosome can be selected by screening for the presence of both SM4 and SM5.

[0062] All colonies produced in the first stage of these transposition methods can inducibly encode Tnp2. To induce expression of Tnp2, a colony or set of colonies are inoculated into a selection-free liquid medium containing an inducing agent. The choice of an inducing agent is entirely up to the convenience of the user and has no bearing upon the operation of the invention. A suitable inducing agent would be arabinose, where the arabinose promoter is provided upstream of the transposase-encoding sequence on the transposon. Arabinose is preferred because its promoter is tightly regulated. Upon induction, Tnp2 is synthesized, then binds to and interacts with the white pair of transposase-interacting sequences and a second round of transposition results. At some frequency, the transposition is intrachromosomal and as a result, a portion of the chromosome is deleted and the remaining chromosomal material is recircularized. Accordingly, a somewhat smaller chromosome results. The only evidence of the second transposition event is one residual mismatched pair of end sequences as is shown in Fig. 5.

[0063] One can readily screen for those colonies that contain a true deletion event. After induction of the second transposase and overnight growth to permit *in vivo* transposition, the cells are diluted and plated without drug selection (e.g., on TYE plates). Then, individual colonies are replica plated either on permissive medium or on medium containing SM4 or SM5. As shown in Fig. 6, all the colonies will grow on the permissive medium, assuming that none has suffered a deletion in an essential gene. However, only those colonies that are also sensitive to both SM4 and SM5 are in fact deletion mutants.

[0064] A similar approach is utilized to permit the excised portion of the chromosome to be replicated and cloned. In this embodiment of the invention, shown in Fig. 7, a simple addition of an origin of replication in the portion of the transposon that is not between the inner (white) pair of transposase-interacting sequences accomplishes this goal. It is important to take due care to ensure that the origin of replication employed is not detrimental or lethal to the host cell. The transposon is introduced into the chromosome as in Fig. 4. Likewise, Tnp2 is induced in precisely the same way. Upon intrachromosomal transposition, however, the excised portion, shown at the bottom right of Fig. 7, contains an origin of replication and can be maintained as an extrachromosomal plasmid.

[0065] Finally, relying upon precisely the same principles as the preceding two embodiments, the next embodiment facilitates insertion of a DNA of interest into the chromosome in place of the deleted portion. In this embodiment, shown in Fig. 8, the insert DNA is provided on the transposon outside of the inner (white) pair of transposase-interacting

sequences but not on the segment of the transposon that includes SM5. This portion of the transposon remains in the chromosome after the second round of transposition. As is shown in Fig. 8, SM5 is lost with the deleted portion of the chromosome while the desired insert is inserted in place of the deleted portion.

[0066] In any of the disclosed embodiments, the products of a first double transposition method can, in fact, act as substrates for a second round of double transposition thereby further increasing the variety of the products. In particular, the chromosomal deletion and gene fusion embodiments are well suited to practicing multiple iterations of the method. By coupling the ability to produce a wide variety of fusion proteins with a known ability to screen for those proteins having desired structures or functions makes the disclosed method of great interest to the pharmaceutical industry, among others. At least the cloning and deletion methods can also be practiced entirely *in vitro* on non-chromosomal targets (e.g., plasmids).

[0067] To obtain products of the methods shown in Figs. 7, one can use a regulated origin of replication on the resulting plasmid to provide additional level of selection. To obtain products of the methods shown in Fig. 8, one can merely replica plate the induced cells and select or screen those that have lost or retained the selectable marker or markers of interest, as appropriate for each method.

[0068] Direct analysis of the random, non-lethal chromosomal deletion products can reveal the largest deletion that can support growth in particular medium. Moreover, because these deletion products leave behind only a small DNA segment and no selectable markers or transposase coding sequences, the process can be performed recursively, such that the deletion product is used in a subsequent round of insertion or deletion. By repeating this process several times, it is possible to reduce the size of the genome, even to the point of producing a bacterial strain that contains a chromosome having only those genes essential for reproduction.

[0069] Additionally, a key requirement in high throughput DNA sequencing is to have a technology in place that will allow a defined primer binding site to be moved next to the region to be sequenced. A single transposition insertion event "randomly" places 2 primer binding sites within a target DNA molecule. In contrast, the double transposition deletion formation system of the invention can advantageously generate multiple constructs from a single transposon insert thereby "moving" a single primer binding site to a plurality of target DNA locations. An embodiment of this methodology is described in the following paragraphs.

[0070] A transposon is constructed with distinct pairs of nested transpose-interacting sequences in inverted orientation relative to each another (as described elsewhere herein). For

example, if the outer pair are IE sequences and the inner pair are ME sequences, the IE sequences with an appropriate Tnp1 are used to generate initial insertions and the ME sequences with an appropriate Tnp2 are used to generate adjoining deletions as described. Appropriately placed inside the element are suitable selective markers and primer binding sites.

[0071] The transposon is inserted at random using the IE specific transposase *in vitro* into a target cloned DNA, such as a BAC clone. The transposon inserted target clone is transformed into cells and independent transformants are isolated and grown up. DNA sequencing is performed using two primers off of the two ends of the transposon inserts.

[0072] From each insert, or from selected inserts, multiple adjacent deletions are generated using Tnp2. This can be accomplished either *in vivo* (requiring prior transformation and then *in vivo* synthesis of transposase) or *in vitro* followed by transformation. A suitable primer is then employed to sequence across the deletion end points into adjacent sequences. Each insert and deletion can also be physically mapped using appropriate restriction digests if desired.

[0073] Although the methods of the invention are exemplified using transposable polynucleotides having two transposase-interacting sequence pairs that interact with two transposases, this is not intended to be a limitation on the invention, since one can engineer any greater number of transposase-interacting sequences into a transposable polynucleotide, as long as a transposase having a distinct activity can be used in combination with each such sequence pair.

Example 1

Restoration of chloramphenicol acetyl transferase (CAT) from N- and C-terminally-truncated genes

[0074] Plasmid Vectors

[0075] Plasmids were maintained in *E. coli* K12 (DH5 α), except plasmids that contained a π -dependent origin of replication which were maintained in EC100 pir-116 cells. Plasmids were purified using a quiafilter midi kit (Quiagen). Pre-cleaved transposons were released from the appropriate purified plasmids by cleavage with a restriction enzyme and were then purified by electrophoresis and gel extraction using the quiaquick gel purification kit (quiagen).

[0076] The plasmid vectors for the first approach to gene fusion were as shown in Fig. 2. A first plasmid containing a kanamycin resistance gene flanked by one IE and one IE/OE linker end (Linker A) was constructed using standard techniques from starting plasmid pGT4 (SEQ ID NO:8) which encodes a kanamycin resistance gene flanked by IE sequences. This plasmid was the source of pre-cleaved transposon, which was released from the resulting plasmid by cleavage

with PshA1. A second plasmid contained a C-terminally truncated CAT gene fragment encoding the first 171 of 219 amino acids and an upstream promoter next to a transposon-interacting sequence specific for ME, as shown at the top of Fig. 2. The source of the CAT gene fragment was pACYC184 (New England Biolabs). The CAT gene was cloned into a vector between ME sequences. The vector also included an origin of replication and a gene conferring resistance to ampicillin. The 3'-end of the gene and the adjacent ME sequence were deleted from the plasmid by cleavage with AflIII and subsequent religation. This plasmid was the target in the first transposition reaction. A comparable approach was taken to generating a third plasmid that contained an N-terminally truncated CAT gene fragment encoding all but the first 38 amino acids. In this case a short PvuII fragment was excised from pACYC184 and then relegated. The third plasmid also included an origin of replication and a gene conferring resistance to tetracycline. This plasmid was the target in the second transposition reaction.

[0077] The plasmid vectors for the second approach to gene fusion were as shown in Fig. 3. The source of pre-cleaved transposon substrate for the first transposition reaction was like that of the first approach, except that Linker A (or, in an alternative embodiment, Linker B) was provided in appropriate orientation at both ends of the transposon that confers resistance to kanamycin. The second plasmid contained a full length CAT gene (Gene A), an origin of replication and a gene that confers ampicillin resistance. The third plasmid contained an N-truncated CAT gene (Gene B) and a pi-dependent origin of replication. It will be appreciated that either the second or the third plasmid can be provided with the pi-dependent origin, which is advantageously used in maintaining members of interest in a library. Similarly, it is understood that the genes provided on the plasmids can be full length or partial length, depending upon the nature of the genes and the goal of the particular transposition process.

Gene fusion protocol

[0078] In all transposition reactions, DNAs were combined with the appropriate Tnp in transposition reaction buffer (0.1 M potassium glutamate, 25 mM Tris acetate, pH 7.5, 10 mM Mg²⁺ acetate, 50 µg/ml bovine serum albumin, 0.5 mM β-mercaptoethanol, 2 mM spermidine, 100 µg/ml tRNA; final concentrations) in a total volume of 20µl. Tnp1 and Tnp2 were purified using the IMPACT system (New England Biolabs) as described previously (Bhasin *et al.*, 1999).

[0079] In the first transposition reaction, pre-cleaved transposon and target plasmid were added to a final concentration of 20nM each. Tnp1 was added to a final concentration of 200nM and the reactions were incubated at 37°C for 3 hours. Products were then subjected to treatment

with SDS (0.5%) and heat (68°C for 5 minutes) to remove Tnp from transposition products and to increase transformation efficiency (data not shown). Treated reaction products were then dialyzed against water and transformed into electrocompetent *E. coli* K12 cells (DH5 α ; efficiency = 8.0×10^8 cfu/ μ l plasmid). Cells were grown at 37°C in 1 ml of Luria-Bertani Medium (LB, Difco) to allow expression of antibiotic resistance genes. The culture was then used to inoculate 50ml of LB containing appropriate antibiotics and grown at 37°C for 16 hours. A small aliquot of culture following the initial 1 hour growth was removed and plated onto agar media to estimate library size ($>10^5$).

[0080] In the second transposition reaction, purified plasmid DNA from the insert library and the second target plasmid were added to a concentration of 80nM each. Tnp2 was then added to a concentration of 400nM. Reactions were allowed to incubate at 37°C for 1 hour and then treated with SDS and heat, dialyzed, and transformed as above.

[0081] In the second approach, the initial insert library was generated by mixing pre-cleaved transposon having Linker A at both of its ends with a target plasmid that contained sequences for the N-terminal truncation of the CAT gene in the presence of Tnp1. The library was transformed into *E. coli* host cells which were outgrown in 1 ml of LB without drugs for 1 hour and subsequently inoculated into 50ml LB and allowed to grow overnight in the presence of double antibiotic selection. The insert library was then purified. In the second reaction, plasmid DNA from the insert library was then mixed with the second plasmid that contained that contained sequences for the C-terminal truncation of the CAT gene. Tnp2 was added to cleave N-terminal fragments from the CAT gene in the insert library and insert them randomly into the second target plasmid. The reaction products were then transformed into *E. coli* host cells and plated on LB agar containing 20 μ g/ml chloramphenicol to select for functional CAT fusions.

[0082] Although successful, Linker A was inefficient, so Linker B was tested in the same way. Due to the order in which the two plasmids were used, the linker orientation for fused genes was in the opposite direction (ME to IE) to those created by method one.

[0083] Gel electrophoresis confirmed that the plasmid fusion libraries of the second approach contained one major band, indicating that the double drug selection efficiently chose the desired products from the second transposition reaction without prior purification. Fusion plasmids were shown to contain a unique EcoRV site from the first target plasmid and a unique ScaI site from the second target plasmid. Double digestion of a single fusion plasmid yielded two linear DNA bands having a combined size equal to that of the fused plasmids (not shown). However, as expected, a smear of DNA bands of varying size was observed when the library was

double-digested with EcoRV and ScaI because the size of the two bands in each fusion plasmid is different, given that the two plasmids fuse at random positions in each individual product.

[0084] To confirm the presence of the transposon linker sequence and to determine the amino acid sequence of the functional fusions, plasmid DNA from a few chloramphenicol resistant colonies obtained in each approach were purified and sequenced. No matter which approach was taken, functional fusions were obtained. Eight functional fusions (obtained from both approaches) were analyzed. None was a 'perfect' fusion (showing no loss or duplication of amino acids). Seven of the eight included a duplicated CAT fragment, ranging in length from 5 amino acids to 54 amino acids in length. One fusion was formed by a 9 amino acid deletion.

[0085] Structural information for the CAT protein used in this study, which originates from transposon Tn9, does not exist. However, X-ray crystallographic structure information is available for the related type III Chloramphenicol Acetyltransferase (CATIII) (Leslie, 1990). A BLAST alignment of the primary amino acid sequences of CAT and CATIII revealed that the two proteins have 46% amino acid identity with only a single gap. This alignment was used to map the location of linker insertion in functional CAT fusions to the CATIII structure. This analysis predicts that, of the sixteen linker-CAT junctions, 15 are inserted in disordered regions, while the remaining junction is predicted to be inserted into a β -sheet one amino acid from the terminus. Although these results come from only one protein fusion example, the analysis strongly suggests that functional fusions are formed when the linker sequence does not insert into a location that interrupts either α -helices or β -sheets.

Example 2

Deletions and Identification of Essential Genes

[0086] Media. For all experiments we used Luria broth liquid or plates media adjusted with antibiotics if needed as follow: chloramphenicol 20 mg/L, kanamycin 40 mg/L, ampicillin 100 mg/L.

[0087] Bacterial strains. E.coli K12 strain MG1655 with a known sequence of chromosomal DNA (Blattner et al. 1997) was used for making deletions. E.coli K12 strain DH5 α (Sambrook et al. 1989) was used for DNA manipulations.

[0088] Fig. 9 depicts the transposons used in this Example. Transposon TnDEL7 was designed for inducing deletion of dispensible genetic material and does not have an origin of replication, thereby allowing the immediate isolation of deletions after induction. Transposon

TnDEL8 contains a conditional (regulated) origin of replication and was used to maintain deleted genetic material in the cell on a plasmid until elimination is triggered, as described below. The selectable markers and other attributes of each transposon are as shown in Fig. 9. Both transposons Tn5DEL7 and Tn5DEL8 were cleaved from donor vectors pGT7 (SEQ ID NO:9) and pGT8 (SEQ ID NO:10), respectively, by restriction enzyme digestion using PshAI and were extracted from agarose gel using QIAquick Gel Extraction Kit (Qiagen).

[0089] Both transposons contain nested pairs of transposase-interacting sequences. The outer pair of sequences are Tn5 IE ends that can participate in forming synaptic complexes in the presence of Tnp1. The inner pair of sequences are ME artificial ends that can participate in transposition reactions in the presence of Tnp2. This efficient combination is preferred, as high transposition efficiency is important for effective screening without selection.

[0090] In the following trials, transposome synaptic complexes were introduced into cells by electroporation. Km^R and Cm^R colonies were selected. For Tn5DEL7, 50 to 80 percent of transposition events were recovered, with a quarter having deletions of desired orientation. For Tn5DEL8 the percent of successful deletion events exceeds 95%, presumably due to negative consequences of having two active origins of replication on the chromosome.

[0091] Depending upon the task, single colonies, or a pooled collection of about 50 colonies, were used to start liquid cultures. At an early exponential growth state, arabinose was added to induce a second transposition step. In the case of TnDEL8, chloramphenicol and IPTG were also added. IPTG maintains plasmids formed during deletion induction and to depress growth of cells in which the transposon-encoded ori did not excise from the chromosome during induction. This creates a selection against such cells. After a few hours, cells were sub cultured in the same media with 100-fold dilution and left shaking overnight. Then, cells were diluted and plated to yield single colonies for replica plating. Km^S, Cm^S cells were picked in the case of TnDEL7 and Km^S cells in the case of TnDEL8. In the latter case, plasmid DNA was prepared for analysis.

[0092] First, deletion size distribution was examined in the lactose operon region. This region was chosen for study since it is known to allow large deletions of at least 100Kb (Bachmann, 1996). Tn5DEL7 was delivered as a synaptic complex into *E. coli* MG1655 cells that were then plated on Lactose-McConkey's medium with antibiotic selection. *E. coli* MG1655 with the deletion transposon inserted into the *lac* operon was isolated. A few white colonies were selected from thousands of red colonies. One colony was chosen for sequencing of the chromosomal DNA around the transposition site. The insert was located at 362,522-31bp of the

E. coli map. A single colony having the *lac* phenotype was selected and DNA sequencing was performed to determine the location of the insertion.

[0093] Then deletion formation was induced by induction of Tnp2 with arabinose and the deletions were collected by replica plating. Screening for deletions in the case of Tn5DEL7 was made by replica plating colonies on LB agar, LB-kanamycin (20mg/L), and LB-chloramphenicol (20mg/L). Cells sensitive to kanamycin were considered to have undergone transposition, and cells sensitive to both drugs were considered to have a deletion of adjacent DNA and the “right” portion of the transposon with only a small transposon linker being left on the chromosome.

[0094] A total of 9 independent deletions were analyzed by sequencing performed on ABI PRISM model 377, either directly from chromosomal DNA or by an inverse PCR technique. For *lacZ* insertion, direct chromosomal DNA sequencing was performed using primer FWD2: 5'CAGATCTCATGCAAGCTTGAGCTC 3' (SEQ ID NO:5), complementary to the transposon linker. For sequencing deletions produced from this insertion, inverse PCR was performed with primers GGTCTGCTTTCTGACAACTCGGGC (SEQ ID NO:6), and ACGCGAAATACGGGCAGACATGGCC (SEQ ID NO:7). after digesting the chromosomal DNA with *FspI* and ligating. PCR products were purified from an agarose gel and sequenced with the standard Big Dye protocol. Of these nine deletions, two events were insertions within the transposon that resulted in loss of chloramphenicol resistance. The remaining seven were desirable events that deleted various lengths of chromosomal DNA. The summary of the sequencing analysis is shown in Fig. 10. The deletions vary in size from 4 to 23Kb, with most deletions being about 20Kb. The average deletion size is both surprising and encouraging. First, transposon attacking its own DNA is expected to find the target at a distance just beyond the persistence length, which is expected to be about 100 to 200 base pairs in the cell. Secondly, with deletions of this size, it is feasible to reach saturation (no further deletions without deleting essential genes), under conditions that permit repetitive application of the technology in a reasonable time frame.

Recursive deletion formation

[0095] Advantageously, all transposon components, apart from a short linker (64bp), are lost after a deletion is generated using this system. The loss of the transposase gene ensures that the chromosome remains stable (in terms of subsequent transposition transposition). The loss of all selectable markers provides an opportunity to iteratively repeat the process.

[0096] Accordingly, 20 consecutive rounds of deletions were induced in MG1655 cells as follows. The protocol was applied repeatedly to mixtures of at least 10 independent deletions, thereby avoiding isolating deleterious deletions that result in delayed cell growth in a mixed culture. After 20 rounds, ten final strains having growth rates at least equal to that of the parental strain were obtained. After analyzing the new strains for the loss of metabolic activities, it was concluded that the strains are in part interrelated and in part independent.

[0097] To analyze the diversity and average size of deletions in these isolates, four isolates were digested with NotI and the digests were separated by pulse field electrophoresis using a CHEF-DR II BioRad system, according to the protocol of Heath et al., 1992, with minor technical modifications. The pattern for MG1655 matches that previously reported, and the identification letter for each fragment is shown at right. For each deletion strain, the pattern is altered and indicates a loss of DNA. The size of each new band in the four deletion strains was estimated by comparison to DNA markers. In some cases, bands seen in digested MG1655 DNA are absent, replaced in the isolates by shorter or longer fragments. The total amount of DNA deleted for four of the isolated strains was calculated as 250, 262, 100, and 247kb. Thus an average deletion size per round is 11 kb, which agrees well with results obtained for the lactose operon region. It is assumed that the size of some deletions is limited by the presence of nearby essential genes. This suggests that large pieces of DNA can frequently be deleted during the first random chromosomal insertions. In other words, *E.coli* has significant excess DNA for growth in rich media. Second, 20 rounds are insufficient to saturate the chromosome with deletions.

Coupled chromosomal deletion / plasmid formation system.

[0098] The obvious limitation of the deletion formation system, described above is the inability to introduce deletions that involve essential genes. It would be advantageous to save deleted DNA conditionally in the same cell and to attempt to eliminate it later. Transposon Tn5DEL7 was, therefore, modified to include a conditional origin of replication, namely the origin from pAM34 (ATCC 77185). The conditional origin was easily controlled by IPTG, maintained moderate copy number, was lost relatively quickly under nonpermissive conditions, and was competent to accommodate large inserts. Importantly, the origin characteristically shows very low background on selective media with selection for the presence of drug resistance or essential gene. Only one or two colonies can arise on a plate lacking IPTG.

[0099] The protocol is as follows. Synaptic complexes were formed by mixing Tnp1 with precut Tn5DEL8 in binding buffer. Transposome complexes were assembled by incubation of

precut transposon with Tnp1, 20 mM Tris Ac, 100 mM K Glutamate for 1h at 37 °C. Molar ratio was attempted to be 1:5, DNA : protein, with DNA concentration of 0.1ug/ul.

[00100] The complexes were introduced into electrocompetent cells at standard recommended conditions (2.5Kv, 5mS). Km^R, Cm^R colonies were selected in the first transposition selection. Individual colonies were inoculated into liquid media. At this point 0.4% arabinose and 1 mM IPTG were added and the cultures were aerated with shaking in 4ml volume in 20ml tubes at 37°C. Arabinose induces synthesis of Tnp2 and, hence, subsequent transposition events. IPTG supports maintenance of the plasmids containing DNA deleted from the chromosome. The cells of interest were kanamycin sensitive and chloramphenicol resistant, since replication of excised DNA circles was supported by keeping 1mM IPTG in the media. Plasmids were detected in more than 90% of cases, indicating strong selection against active extra origin of replication on the chromosome.

[00101] Table 1 shows the final products obtained for 15 independent insertions of Tn5DEL8. The largest plasmid for each case was analyzed by sequencing to define the initial insertion position and the extent of deletion. To determine whether the deleted DNA in each plasmid was essential, cells were streaked on rich media with no IPTG. In the absence of IPTG, the extrachromosomal plasmid, which containing the excised sequences, is lost. In some cases individual colonies did not form, indicating a dependence on the plasmid. The simplest cases is isolate 12.17. Only gene dnaK is deleted; it is known to be essential. In isolate 14.17, one of two genes (rpoZ and gmk) is essential. For insertion #4 three plasmids were analyzed to define DNA carrying essential genes. The difference in size among the plasmids is minimal, but the difference in consequences of elimination of plasmids is dramatic. Plasmids 4.6 and 4.9 differ by two genes, glyS and glyQ. Although strain 4.6 can grow without IPTG, strain 4.9 cannot. Thus, at least one of the genes excised in isolate 4.9 is essential. With the exception of these genes, all other ORFs (complete or interrupted) can be considered non-essential (at least for growth in rich media).

[00102] For both strategies described here, deletions were obtained without direct selection as would be required for, e.g., SucB or GalK. That would require transposons to be larger and more importantly, would restrict the system to use with *E.coli*.

[00103] This Example demonstrates the proof of principle for creating a list of essential and nonessential bacterial genes. It is, accordingly, now technically possible to create a representative library of deletions/complementary plasmids covering a genome multiple times. Then systematic sequencing of deletion borders, in combination with tests of survival after

eliminating the complementary plasmids can provide an extensive (ideally complete) set of genes that can be eliminated without detrimental consequences to the cell.

[00104] The present invention is not intended to be limited to the foregoing, but rather encompasses all such variations and modifications apparent to the skilled artisan that fall within the scope of the appended claims.

TABLE 1

Insert #	Δ #	Insert End	Δ End	Size	Partial ORFs	Complete ORFs	Grow w/o IPTG
1	1.3	1073109	1094823	21714	b1028;b1012	b1013;putA;putP;b1016-1018;ycdB;phoH;b1021-1025;tra5_3;b1027	Y
2	2.8	2776930	2770104	6826	b2638;b2647	b2639-b2646	Y
3	3.1	4407731	4403605	4126	yjfl	yjaB;vacB;yjfh	Y
4	4.2	3735047	3725227	9821	yiaB	xyIB;xyIA;xyIF;xyIG;xyIH;xyIR;b3570	Y
4	4.6	3735047	3723521	11526	none	yiaH;yiaA;yiaB;xyIB;xyIA;xyIF;xyIG;xyIH;xyIR;b3570	Y
4	4.9	3735047	3719490	15557	yibb	glyS;glyQ;yiaH;yiaA;yiaB;xyIB;xyIA;xyIF;xyIG;xyIH;xyIR;b3570	N
5	5.1	1224154	1210042	14112	mcra;minD	b1160-b1173;minE	Y
6	6.2	3045069	3042244	2825	bglA;gcvP	yglF	Y
7	7.1	2779269	2767042	12227	b2633;b2647	b2634-b2646	Y
8	8.4	3882592	3882500	92	none	none	Y
9	9.7	4589240	4595093	5853	mdoB;tsr	yjN;yjM;b4356	Y
10	10.3	4141018	4117696	23322	menA;trwC	hslU;hslV;ftsN;cytR;prfA;rpmE;yjiX;metJ;metB;metL;metF;katG;yjiE;yjiF;gldA;talC;ptsA;yjiI	N
11	11.3	2793099	2795902	2803	gabP;b2668	ygaE;b2665-b2667	Y
12	12.17	14166	12088	2078	none	dnaK	N
13	13.19	4542104	4546611	4507	fimC;fimH	fimD;fimF;fimG	Y
14	14.17	3821524	3818998	2526	spoT	rpoZ;gmk	N
15	15.17	1570686	1544492	26194	yddC;yddG	fdnG;fdnH;fdnI;b1477;b1478;sfca;rpsV;b1481;osmC;b1483-1491;xasA;gadB	Y

CLAIMS

WE CLAIM:

1. A polynucleotide comprising distinct first and second transposase-interacting inverted repeat sequence pairs, each sequence pair having a specificity for binding to and interacting with a distinct transposase enzyme, members of the first sequence pair flanking members of the second sequence pair.
2. A polynucleotide as claimed in Claim 1 wherein the first or second transposase-interacting inverted repeat sequence pair comprises Tn5 wild-type inside end sequences.
3. A polynucleotide as claimed in Claim 1 wherein the first or second transposase-interacting inverted repeat sequence pair comprises Tn5 mosaic end sequences.
4. A polynucleotide as claimed in Claim 1 wherein the first or second transposase-interacting inverted repeat sequence pair comprises Tn5 wild-type outside end sequences.
5. A polynucleotide as claimed in Claim 1 further comprising between the members of the second inverted repeat sequence pair a first sequence for conferring selectability upon a host cell.
6. A polynucleotide as claimed in Claim 5 further comprising, between the members of the second inverted repeat sequence pair, a polynucleotide that encodes a transposase that specifically binds to and interacts with the second sequence pair and still further comprising, between a first adjacent pair of distinct inverted repeat sequences, a second sequence for conferring selectability upon a host cell.

7. A polynucleotide as claimed in Claim 6 further comprising an origin of replication between the first adjacent pair of distinct inverted repeat sequences.

8. A polynucleotide as claimed in Claim 6 further comprising a preselected polynucleotide sequence insert between a second adjacent pair of distinct inverted repeat sequences.

9. A method for producing a gene fusion library, the method comprising the steps of: mixing together, under conditions suitable for *in vitro* transposition, (1) copies of a transposable polynucleotide that comprises distinct first and second transposase-interacting inverted repeat sequence pairs, members of the first sequence pair flanking members of the second sequence pair, the members of the second sequence pair flanking a first sequence for conferring selectability upon a host cell, (2) copies of a first target nucleic acid molecule that comprises a first polypeptide-encoding gene sequence, a first origin of replication and a second sequence for conferring selectability upon a host cell, and (3) a first transposase that binds to and interacts with the first sequence pair, to produce first transposition products;

introducing the first transposition products into host cells;

selecting host cells that comprise first transposition products wherein the first polypeptide-encoding gene sequence is disrupted by the transposable polynucleotide;

mixing (1) the transposition products from the selected host cells and (2) a second target nucleic acid molecule that comprises a second polypeptide-encoding gene sequence, a second origin of replication and a third sequence for conferring selectability upon a host cell, and (3) a second transposase that binds to and interacts with the second sequence pair, to produce second transposition products;

introducing the second transposition products into host cells;

selecting host cells that comprise second transposition products comprising fusions between the first and the second polypeptide-encoding gene sequences.

10. A method as claimed in Claim 9 wherein the first origin of replication is a conditional origin of replication.

11. A method as claimed in Claim 9 wherein the second origin of replication is a conditional origin of replication.

12. A method for deleting a portion of a chromosome of a host cell, the method comprising the steps of:

introducing into the host cell a synaptic complex comprising (1) a first transposase and (2) a transposable polynucleotide that comprises distinct first and second transposase-interacting inverted repeat sequence pairs, members of the first sequence pair flanking members of the second sequence pair, further comprising between the members of the second inverted repeat sequence pair a first sequence for conferring selectability upon a host cell and a polynucleotide that encodes a second transposase that specifically binds to and interacts with the second sequence pair and still further comprising, between a first adjacent pair of distinct inverted repeat sequences, a second sequence for conferring selectability upon a host cell;

selecting host cells in which the transposable polynucleotide has integrated into the chromosome;

inducing expression of the second transposase in the selected host cells; and
screening to isolate cells in which a portion of the chromosome is deleted.

13. A method for cloning a portion of a chromosome of a host cell, the method comprising the steps of:

introducing into the host cell a synaptic complex comprising (1) a first transposase and (2) a transposable polynucleotide that comprises distinct first and second transposase-interacting inverted repeat sequence pairs, members of the first sequence pair flanking members of the second sequence pair, further comprising between the members of the second inverted repeat sequence pair a first sequence for conferring selectability upon a host cell and a polynucleotide that encodes a second transposase that specifically binds to and interacts with the second sequence pair and still further comprising, between a first adjacent pair of distinct inverted repeat sequences, a second sequence for conferring selectability upon a host cell and an origin of replication;

selecting host cells in which the transposable polynucleotide has integrated into the chromosome;

inducing expression of the second transposase in the selected host cells; and

screening to isolate cells in which a portion of the chromosome is cloned onto a self-replicating nucleic acid molecule that comprises the origin of replication.

14. A method for inserting a preselected polynucleotide sequence insert into a chromosome of a host cell, the method comprising the steps of:

introducing into the host cell a synaptic complex comprising (1) a first transposase and (2) a transposable polynucleotide that comprises distinct first and second transposase-interacting inverted repeat sequence pairs, members of the first sequence pair flanking members of the second sequence pair and comprising between the members of the second inverted repeat sequence pair a first sequence for conferring selectability upon a host cell and a polynucleotide that encodes a second transposase that specifically binds to and interacts with the second sequence pair and further comprising, between a first adjacent pair of distinct inverted repeat sequences, a second sequence for conferring selectability upon a host cell and further comprising, between a second adjacent pair of distinct inverted repeat sequences, the preselected polynucleotide sequence insert;

selecting host cells in which the transposable polynucleotide has integrated into the chromosome;

inducing expression of the second transposase in the selected host cells; and

screening to isolate cells in which the preselected polynucleotide sequence insert is inserted into the chromosome and the second sequence for conferring selectability upon a host cell is lost from the chromosome.


15. A polynucleotide fusion product between portions of first and second genes that encodes a polypeptide fusion, wherein the portions of the first and second genes are linked by a pair of non-identical transposase-interacting sequences.

16. A chromosome lacking at a site a portion of nucleic acid and comprising at the site a pair of non-identical transposase-interacting sequences.

17. A chromosome containing at a site an inserted portion of nucleic acid flanked by a pair of non-identical transposase-interacting sequences.

18. A self-replicating nucleic acid molecule comprising a pair of non-identical transposase-interacting sequences flanking a portion of a chromosome and an origin of replication.

FIG 1



2/10




FIG 2

3/10





FIG 3

4/10

Chromosomal insertion of transposon via co-delivery.**FIG 4**

5/10

In vivo transposition.





FIG 5

6/10

Screen for chromosomal deletions.



$$SM4^R + SM5^R = \text{No transposition}$$

$$SM4^S + SM5^R = \text{Transposition event: Inversion or 'wrong' deletion}$$

$$SM4^S + SM5^S = \text{Transposition event: Deletion}$$

FIG 6

7/10

Direct cloning of chromosomal DNA.




FIG 7

8/10

Insertion of DNA and removal of drug marker.





FIG 9






FIG 10

SEQUENCE LISTING

<110> Goryshin, Igor Y
Naumann, Todd A
Reznikoff, William S

<120> DOUBLE TRANSPOSITION METHODS FOR MANIPULATING NUCLEIC
ACIDS

<130> 960296.97541

<140>

<141>

<150> 60/251482

<151> 2000-12-05

<160> 10

<170> PatentIn Ver. 2.1

<210> 1

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: LINKER A (FULL
LENGTH)

<400> 1

ctgtctcttg atcagatcta cttgtgtata agagtcag

38

<210> 2

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: LINKER A
(COMPRESSED)

<400> 2

ctgtctcttg atcagatgtg tataagagtc ag

32

<210> 3

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: LINKER B (FULL
LENGTH)

<400> 3

ctgtctcttg atcagatcta gatgtgtata agagacag

38

<210> 4
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: LINKER B
(COMPRESSED)

<400> 4
ctgtctcttg atcagatgtg tataagagac ag 32

<210> 5
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER FWD2

<400> 5
cagatctcat gcaagcttga gctc 24

<210> 6
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER

<400> 6
ggtctgcttt ctgacaaact cgggc 25

<210> 7
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PRIMER

<400> 7
acgcgaaata cgggcagaca tggcc 25

<210> 8
<211> 3277
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Pgt4

<400> 8
gacagctgtc tcttgatcag atctcatgca agcttggctg cagggggggg gggaaagcca 60

cgttgtgtct	caaaatctct	gatgttacat	tgcacaagat	aaaaatatat	catcatgaac	120
aataaaactg	tctgcttaca	taaacagtaa	tacaaggggt	gttatgagcc	atattcaacg	180
ggaaacgtct	tgctcgaggc	cgcgattaaa	ttccaacatg	gatgctgatt	tatatgggta	240
taaatgggct	cgcgataatg	tcgggcaatc	aggtgcgaca	atctatcgat	tgtatgggaa	300
gcccgatgcg	ccagagttgt	ttctgaaaca	tggcaaaggt	agcgttgcca	atgatgttac	360
agatgagatg	gtcagactaa	actggctgac	ggaatttatg	cctcttccga	ccatcaagca	420
ttttatccgt	actcctgatg	atgcatgggt	actcaccact	gcgatccccg	ggaaaacagc	480
attccaggta	ttagaagaat	atcctgattc	aggtgaaaat	attggtgatg	cgctggcagt	540
gttccctgcg	cggttgcatt	cgattccctgt	ttgtaattgt	cctttttaaca	gcgatcgctg	600
atthcgtctc	gctcaggcgc	aatcacgaat	gaataacggt	ttgggtgatg	cgagtgattt	660
tgatgacgag	cgtaatggct	ggcctgttga	acaagtctgg	aaagaaatgc	ataagctttt	720
gccattctca	ccggattcag	tcgtcactca	tggtgatttc	tcacttgata	accttatttt	780
tgacgagggg	aaattaatag	gttgtattga	tggtggacga	gtcgggaatcg	cagaccgata	840
ccaggatctt	gccatcctat	ggaactgcct	cggtgagttt	tctccttcat	tacagaaacg	900
gctttttcaa	aaatatggta	ttgataatcc	tgatatgaat	aaattgcagt	ttcattttgat	960
gctcgatgag	tttttctaata	cagaattgggt	taattgggtg	taacactggc	agagcattac	1020
cgtgacttga	cgggacggcg	gctttgttga	ataaatcgaa	cttttgctga	gttgaaggat	1080
cagatcacgc	atcttcccga	caacgcagac	cggtccgtgg	caaagcaaaa	gttcaaaatc	1140
accaactggt	ccacctacaa	caaagctctc	atcaaccgtg	gtccctcac	tttctggctg	1200
gatgatgggg	cgattcaggc	ctggtatgag	tcagcaacac	cttcttcacg	aggcagacct	1260
cagcgccccc	ccccccctgc	aggtcgactc	tagaggatcc	ccgggtaccg	agctcgaatt	1320
cagatctgat	caagagacag	ctgtcgacgt	caggtggcac	ttttcgggga	aatgtgcgcg	1380
gaacccctat	ttgtttatth	ttctaataac	attcaaatat	gtatccgctc	atgagaccaat	1440
aaccctgata	aatgcttcaa	taatattgaa	aaaggaagag	tatgagtatt	caacatttcc	1500
gtgtcgccct	tattccctth	tttgcgcat	tttgcccttc	tgthtttgct	caccagaaa	1560
cgctggtgaa	agtaaaagat	gctgaagatc	agttgggtgc	acgagtgggt	tacatcgaac	1620
tggatctcaa	cagcggtaag	atccttgaga	gttttcgccc	cgaagaacgt	tttccaatga	1680
tgagcaactth	taaagtthctg	ctatgtggcg	cggattatc	ccgtattgac	gccgggcaag	1740
agcaactcgg	tcgccgcata	cactattctc	agaatgactt	ggttgagtac	tcaccagtca	1800
cagaaaagca	tcttacggat	ggcatgacag	taagagaatt	atgcagtgc	gccataacca	1860
tgagtataaa	cactgcggcc	aacttacttc	tgacaacgat	cggaggaccg	aaggagctaa	1920
ccgctthttt	gcacaacatg	ggggatcatg	taactcgcct	tgatcgttgg	gaaccggagc	1980
tgaatgaagc	cataccaaac	gacgagcgtg	acaccacgat	gcctgtagca	atggcaacaa	2040
cgttgcgcaa	actattaact	ggcgaactac	ttactctagc	ttcccggcaa	caattaatag	2100
actggatgga	ggcgataaaa	gttgccaggac	cacttctgcg	ctcgccctt	cgggtggct	2160
ggthttattgc	tgataaatct	ggagccggtg	agcgtgggtc	tcgcggtatc	attgcagcac	2220
tggggccaga	tggtaaagccc	tcccgtatcg	tagttatcta	cacgacgggg	agtcaggcaa	2280
ctatggatga	acgaaataga	cagatcgctg	agataggtgc	ctcactgatt	aagcattgggt	2340
aactgtcaga	ccaagtthac	tcataatatac	tttagattga	tttaaaactt	cattthtaat	2400
ttaaaaggat	ctaggtgaag	atcctthttg	ataatctcat	gacaaaatc	ccttaacgtg	2460
agthtttcgtt	ccactgagcg	tcagaccccg	tagaaaagat	caaaggatct	tcttgagatc	2520
ctthttttct	gcgcgtaatc	tgctgcttgc	aaacaaaaaa	accaccgcta	ccagcgggtg	2580
tttgthttgcc	ggatcaagag	ctaccaactc	ttthtccgaa	ggtaactggc	ttcagcagag	2640
cgcagatacc	aaatactgtc	cttctagtgt	agccgtagtth	aggccaccac	ttcaagaact	2700
ctgtagcacc	gcctacatac	ctcgtctctg	taattcctgtt	accagtggct	gctgccagtg	2760
gcgataagtc	gtgtcttacc	gggttggaact	caagacgata	gttaccggat	aaggcgcgac	2820
ggtcgggctg	aacgggggggt	tcgtgcacac	agcccagctt	ggagcgaacg	acctacaccg	2880
aactgagata	cctacagcgt	gagctatgag	aaagcgccac	gcttcccgaa	gggagaaagg	2940
cggacaggta	tccggtgaagc	ggcagggctg	gaacaggaga	gcgcacgagg	gagcttccag	3000
ggggaaacgc	ctggtatctt	tatagtcctg	tcgggtthtcg	ccacctctga	cttgagcgtc	3060
gaththttgtg	atgctcgtca	ggggggcgga	gcctatggaa	aaacgccagc	aacgcggcct	3120
thtttacggtt	cctggccctt	tgctggccct	ttgctcacat	gttctthtct	gcgttatccc	3180
ctgattctgt	ggataaccgt	attaccgcct	ttgagtgcgc	tgataccgct	cgcgcgagcc	3240
gaacgaccga	gcgcagcgag	tcagtgcgag	aggaagc			3277

<210> 9

<211> 7814

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Pgt7

<400> 9

gacagctgtc	tcttgatcag	atctcatgca	agcttcagct	caotcactca	agatgtgtat	60
aagagacagt	cgagatcccc	gccacggttg	atgagagctt	tggtttaggt	ggaccagttg	120
gtgattttga	acttttgctt	tgccacggaa	cggtctgcgt	tgtcgggaag	atgcgtgatc	180
tgatccttca	actcagcaaa	agttcgattt	attcaacaaa	gccgccgtcc	cgtaagtc	240
gcgtaatgct	ctgccagtgt	tacaaccaat	taaccaattc	tgattagaaa	aactcatcga	300
gcatcaaatg	aaactgcaat	ttattcatat	caggattatc	aataccatat	ttttgaaaaa	360
gccgtttctg	taatgaagga	gaaaactcac	cgaggcagtt	ccataggatg	gcaagatcct	420
ggtatcggtc	tgcgattccg	actcgtccaa	catcaatata	acctattaat	ttcccctcgt	480
caaaaataag	gttatcaagt	gagaaatcac	catgagtgc	gactgaatcc	ggtgagaatg	540
gcaaaagtgt	atgcatttct	ttccagactt	gttcaacagg	ccagccatta	cgctcgtcat	600
caaaatcact	cgcatcaacc	aaaccgttat	tcattcgtga	ttgcgcctga	gcgagacgaa	660
atacgcgatc	gctgttaaaa	ggacaattac	aaacaggaat	cgaatgcaac	cggcgagga	720
acactggcat	cgcataca	atattttcac	ctgaatcagg	atattcttct	aatacctgga	780
atgctgtttt	tccggggatc	gcagtgggtga	gtaaccatgc	atcatcagga	gtacggataa	840
aatgcttgat	ggtcgggaaga	ggcataaatt	ccgtcagcca	gtttagtctg	accatctcat	900
ctgtaacatc	attggcaacg	ctacctttgc	catgtttcag	aaacaactct	ggcgcatcgg	960
gcttcccata	caatcgatag	attgtcgcac	ctgattgccc	gacattatcg	cgagcccatt	1020
tatacccata	taaatcagca	tccatgttg	aatttaaatcg	cggcctcgag	caagacgttt	1080
cccgttgaat	atggctcata	acacccttg	tattactggt	tatgtaagca	gacagtttta	1140
ttgttcatga	tgatatat	ttatcttctg	caatgtaaca	tcagagattt	tgagacacaa	1200
cggtgctttc	ccccccccc	ctatgcggtg	tgaaataccg	cacagatgcg	taaggagaaa	1260
ataccgcgatc	aggacgcgc	ctgtagcggc	gcattaagcg	cggcggtgt	ggtggttacg	1320
cgcagcgtga	cgctacactt	gccagcggc	tagcggccgc	tcctttcgt	ttcttccctt	1380
cctttctcgc	cacgttcgcc	atgcataatg	tgctgtcaa	atggacgaag	cagggattct	1440
gcaaacctta	tgctactccg	tcaagccgtc	aattgtctga	ttcgttacca	attatgacaa	1500
cttgacggct	acatcattca	ctttttcttc	acaaccggca	cggaaactcg	tcgggctggc	1560
cccgtgcat	tttttaaaata	cccgcgagaa	atagagttga	tcgtcaaaac	caacattgcg	1620
accgacgggtg	gcgataggca	tccgggtggt	gctcaaaagc	agcttcgcct	ggctgatacg	1680
ttggtcctcg	cgccagctta	agacgcta	ccctaactgc	tggcggaaaa	gatgtgacag	1740
acgcgacggc	gacaagcaaa	catgctgtgc	gacgctggcg	atatcaaaat	tgctgtctgc	1800
caggtgatcg	ctgatgtact	gacaagcctc	gcgtaccoga	ttatccatcg	gtggatggag	1860
cgactcgtta	atcgcttcca	tgccgcgcag	taacaattgc	tcaagcagat	ttatcgccag	1920
cagctccgaa	tagcgcctt	ccccttgccc	ggcggtta	atgttgcctt	acaggtcgt	1980
gaaatgcggc	tggtgcgctt	catccggggc	aaagaacccc	gtattggcaa	atattgacgg	2040
ccagttaagc	cattcatgcc	agtaggcgcg	cggacgaaag	taaaccact	ggtgatacca	2100
ttcgcgagcc	tccgatgac	gaccgtagt	atgaatctct	cctggcgagg	acagcaaaat	2160
atcaccgggt	cggcaacaa	attctcgtcc	ctgatttttc	accacccctt	gaccgcgaat	2220
ggtgagattg	agaatataac	ctttcattcc	cagcggctcg	tcgataaaaa	aatcgagata	2280
accgttggcc	tcaatcggcg	ttaaaccgcg	caccagatgg	gcattaaacg	agtatcccg	2340
cagcaggga	tcattttgcg	cttcagccat	acttttcata	ctcccgccat	tcagagaaga	2400
aaccaattgt	ccatattgca	tcagacattg	ccgtcactgc	gtcttttact	ggctcttctc	2460
gctaaccaaa	ccgtaaccc	cgcttattaa	aagcattctg	taacaaagcg	ggaccaaagc	2520
catgacaaaa	acgcgtaaca	aaagtgtcta	taatcacggc	agaaaagtcc	acattgatta	2580
tttgacggc	gtcacacttt	gctatgccat	agcattttta	tcataagat	tagcggatcc	2640
tacctgacgc	tttttatcgc	aactctctac	tgttcttcca	taccggtttt	tttgggctag	2700
aaataatttt	gtttaacttt	aagaaggaga	tataaccatg	ataacttctg	ctcttcatcg	2760
tgcgcccgac	tgggctaaat	ctgtgttctc	ttcgccggcg	ctgggtgatc	ctcgccgtac	2820
tgcccgcttg	gttaacgtcg	ccgcccaatt	ggcaaaatat	tctggtaaat	caataaccat	2880
ctcatcagag	ggtagtaag	ccgccagga	agggccttac	cgatttatcc	gcaatcccaa	2940
cgtttctgcc	gaggcgatca	gaaaggctgg	cgccatgcaa	acagtcaagt	tggctcagga	3000
gtttcccgaa	ctgctggcca	ttgaggacac	cacctctttg	agttatcgcc	accaggtcgc	3060
cgaagagctt	ggcaagctgg	gctctattca	ggataaatcc	cgcggatgg	gggttctact	3120
cgttctcttg	ctcgaggcca	ccacattccg	caccgtagga	ttactgcac	aggagtggg	3180
gatgcgccc	gatgaccctg	ccgatgcgga	tgaaaaggag	agtggcgaat	ggctggcagc	3240
ggccgcaact	agccggttac	gcatgggcag	catgatgagc	aacgtgattg	cggctctgtga	3300

ccgcgaagcc	gatattcatg	cttatctgca	ggacaaactg	gcgcataacg	agcgcttcgt	3360
ggtgcgctcc	aagcacccac	gcaaggacgt	agagtctggg	ttgtatctgt	acgaccatct	3420
gaagaaccaa	ccggagttgg	gtggctatca	gatcagcatt	ccgcaaaagg	gctgtggtgga	3480
taaacgcggt	aaacgtaaaa	atcgaccagc	ccgcaaggcg	agcttgagcc	tgcgcagtg	3540
gcgcatacac	ctaaaacagg	ggaatatcac	gctcaacgcg	gtgctggccg	aggagattaa	3600
cccgcccaag	ggtgagaccc	cgttgaaatg	gttggttgctg	accagcgaac	cggctcagtc	3660
gctagcccaa	gccttgcgcg	tcctcgacat	ttatacccat	cgctggcgga	tcgaggagtt	3720
ccataaggca	tggaaaaccg	gagcaggagc	cgagaggcaa	cgcatggagg	agccggataa	3780
tctggagcgg	atggtctcga	tcctctcggt	tggtgcggtc	aggctgttac	agctcagaga	3840
aagcttcacg	ccgccgaag	cactcagggc	gcaagggtg	ctaaaggaag	cggaaacacgt	3900
agaaaagccag	tccgcagaaa	cgggtgctgac	cccgatgaa	tgctcagctac	tgggctatct	3960
ggacaaggga	aaacgcaagc	gcaaagagaa	agcaggtagc	ttgcagtggtg	cttacatggc	4020
gatagctaga	ctgggcggtt	ttatggacag	caagcgaacc	ggaattgccca	gctggggcgc	4080
cctctggtaa	ggttggggaag	ccctgcaaag	taaactggat	ggctttcttg	ccgccaagga	4140
tctgatggcg	caggggatca	agatctgatc	cggtctttcc	ccgtcaagct	ctaaatcggg	4200
ggctcgactg	tctcttatac	acatcttgag	tgagtggaga	cctgcattaa	tgaatcgggt	4260
accgagctcg	aattacttca	ctgacaccct	catcagtgcc	aacatagtaa	gccagtatac	4320
actccgctag	cgctgatgtc	cggcggtgct	tttgccgtta	cgcaccacco	cgctcagtagc	4380
tgaacaggag	ggacagctga	tagaaacaga	agccactgga	gcacctcaaa	aacaccatca	4440
tacactaaat	cagtaagttg	gcagcatcac	ccgacgcact	ttgcgcccga	taaatacctg	4500
tgacggaaga	tcacttcgca	gaataaataa	atcctgggtg	ccctgttgat	accgggaagc	4560
cctggggcaa	cttttggcga	aatgagacg	ttgatcggca	cgtaagaggt	tccaactttc	4620
accataatga	aataagatca	ctaccgggcg	tattttttga	gttatcgaga	ttttcaggag	4680
ctaaggaagc	taaaatggag	aaaaaaatca	ctggatatac	caccgttgat	atatcccaat	4740
ggcatcgtaa	agaacatttt	gaggcatttc	agtcaagttg	tcaatgtacc	tataaccaga	4800
ccgttcagct	ggatattacg	gcctttttta	agaccgtaaa	gaaaaataag	cacaagtttt	4860
atccggcctt	tattcacatt	cttgcccgcg	tgatgaatgc	tcacccggaa	ttccgtatgg	4920
caatgaaaga	cggtagctg	gtgatatggg	atagtgttca	cccttggttac	accgttttcc	4980
atgagcaaac	tgaacggtt	tcacgcctct	ggagtgaata	ccacgacgat	ttccggcagt	5040
ttctacacat	atattcgcaa	gatgtggcgt	gttacgggtg	aaacctggcc	tatttcccta	5100
aagggtttat	tgagaatatg	tttttcgtct	cagccaatcc	ctgggtgagt	ttcaccagtt	5160
ttgattttaa	cgtggccaat	atggacaact	tcttcgcccc	cgttttcaac	atgggcaaat	5220
attatacgca	aggcgacaag	gtgctgatgc	cgctggcgat	tcagggttcat	catgccgtct	5280
gtgatggctt	ccatgtcggc	agaatgctta	atgaattaca	acagtactgc	gatgagtggc	5340
agggcggggc	gtaatttttt	taaggcagtt	attggtgccc	ttaaacgctt	ggtgctacgc	5400
ctgaataaatt	gataataagc	ggatgaatgg	cagaaattcg	aaagcaaatt	cgacccggtc	5460
gtcgggttcag	ggcagggtcg	ttaaataagcc	gcttatgtct	attgctgggt	taccggttta	5520
ttgactaccg	gaagcagtg	gaccgtgtgc	ttctcaaatg	cctgaggcca	gtttgctcag	5580
gctctccccg	tggaggtaat	aattgacgat	atgatcattt	attctgcctc	ccagagcctg	5640
ataaaaaacg	ttagcgcttc	gttaatacag	atgtagggtg	tcacaggggt	agccagcagc	5700
atcctgcgat	gcagatccgg	aacataatgg	tgcaggggcg	ttgtttcggc	gtgggtatgg	5760
tggcaggccc	cgtggccggg	ggactgttgg	gcgctgcggg	cacctgtcct	acgagttgca	5820
tgataaagaa	gacagtcata	agtgcggcga	cgaaattcag	atctgatcaa	gagacagctg	5880
tcgacgtcag	gtggcacttt	tcggggaaat	gtgcgcggaa	ccctattttg	tttatttttc	5940
taaatacatt	caaataatga	tccgctcatg	agacaataac	cctgataaat	gcttcaataa	6000
tattgaaaaa	ggaagagtat	gagtattcaa	catttccgtg	tcgcccttat	ttcctttttt	6060
gcggcatttt	gccttcctgt	ttttgctcac	ccagaaaacg	tggtgaaagt	aaaagatgct	6120
gaagatcagt	tgggtgcacg	agtgggttac	atcgaactgg	atctcaacag	cggttaagatc	6180
cttgagagtt	ttcgccccga	agaacgtttt	ccaatgatga	gcacttttaa	agttctgcta	6240
tgtggcgcg	tattatcccc	tattgacgcc	gggcaagagc	aactcggtcg	ccgcatacac	6300
tattctcaga	atgacttggt	tgagtactca	ccagtcacag	aaaagcatct	tacggatggc	6360
atgacagtaa	gagaattatg	cagtgtctgc	ataacatga	gtgataaac	tgccggccaac	6420
ttactttctga	caacgatcgg	aggaccgaag	gagctaacgg	cttttttgca	caacatgggg	6480
gatcatgtaa	ctgccttga	tcgttgggaa	ccggagctga	atgaagccat	accaaagcag	6540
gagcgtgaca	ccacgatgcc	tgtagcaatg	gcaacaacgt	tgccgaaact	attaactggc	6600
gaactactta	ctctagcttc	ccggcaacaa	ttaatagact	ggatggaggc	ggataaagtt	6660
gcaggaccac	ttctgcgctc	ggcccttccg	gctggctggt	ttattgctga	taaatctgga	6720
gccggtgagc	gtgggtctcg	cggtatcatt	gcagcactgg	ggccagatgg	taagccctcc	6780
cgtatcgtag	ttatctacac	gacggggagt	caggcaacta	tggatgaacg	aaatagacag	6840
atcgctgaga	taggtgcctc	actgattaag	cattggtaac	tgctcagacca	agtttactca	6900

tatatacttt	agattgattt	aaaacttcat	ttttaattta	aaaggatcta	ggtgaagatc	6960
cttttttgata	atctcatgac	caaaatccct	taacgtgagt	tttcgttcca	ctgagcgtca	7020
gaccccgtag	aaaagatcaa	aggatcttct	tgagatcctt	tttttctgcg	cgtaatctgc	7080
tgcttgcaaa	caaaaaaacc	accgctacca	gcggtggttt	gtttgccgga	tcaagagcta	7140
ccaactcttt	ttccgaaggt	aactggcttc	agcagagcgc	agataccaaa	tactgtcctt	7200
ctagtgtagc	cgtagttagg	ccaccaacttc	aagaactctg	tagcaccgcc	tacatacctc	7260
gctctgctaa	tcctgttacc	agtggctgct	gccagtggcg	ataagtcgtg	tcttaccggg	7320
ttggactcaa	gacgatagtt	accggataag	gcgcagcggg	cgggctgaac	gggggggttcg	7380
tgcacacagc	ccagcttgga	gcgaacgacc	tacaccgaac	tgagatacct	acagcgtgag	7440
ctatgagaaa	gcgccacgct	tcccgaaggg	agaaaggcgg	acaggtatcc	ggtaagcggc	7500
agggtcggaa	caggagagcg	cacgagggag	cttccagggg	gaaacgcctg	gtatctttat	7560
agtctgtcg	ggtttcgcca	cctctgactt	gagcgtcgat	ttttgtgatg	ctcgtcaggg	7620
gggcggagcc	tatggaaaaa	cgccagcaac	gcggcctttt	tacggttcct	ggccttttgc	7680
tggccttttg	ctcacatggt	ctttcctgcg	ttatcccctg	attctgtgga	taaccgtatt	7740
accgcctttg	agtgagctga	taccgctcgc	cgcagccgaa	cgaccgagcg	cagcgagtca	7800
gtgagcgagg	aagc					7814

<210> 10

<211> 9265

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Pgt8

<400> 10

ctaagaaacc	attattatca	tgacattaac	ctataaaaaat	aggcgtatca	cgaggccctt	60
tcgtcttcaa	gggtcgctca	ctgcccgcct	tccagtcggg	aaacctgtcg	tgccagctgc	120
attaatgaat	cggccaacgc	gcggggagag	gcggtttgcg	tattgggcgc	caggggtggt	180
tttcttttca	ccagttagac	gggcaacagc	tgattgccct	tcaccgcctg	gccctgagag	240
agttgcagca	agcgggtccac	gctgggtttgc	cccagcaggc	gaaaatcctg	tttgatggtg	300
gttgacggcg	ggatataaca	tgagctgtct	tcggtatcgt	cgtatccac	taccgagata	360
tccgcaccaa	cgcgagccc	ggactcggtg	atggcgcgca	ttgcgcccag	cgccatctga	420
tcgttggcaa	ccagcatcgc	agtgggaacg	atgccctcat	tcagcatttg	catggtttgt	480
tgaaaaccgg	acatggcact	ccagtcgcct	tcccgttccg	ctatcggctg	aatttgattg	540
cgagttagat	atttatgcca	gccagccaga	cgcagacgcg	ccgagacaga	acttaatggg	600
cccgtataca	gcgcgatttg	ctggtgaccc	aatgcgacca	gatgctccac	gcccagtcgc	660
gtaccgtctt	catgggagaa	aataatactg	ttgatgggtg	tctggtcaga	gacatcaaga	720
aataacgccg	gaacattagt	gcaggcagct	tccacagcaa	tggcatcctg	gtcatccagc	780
ggatagttaa	tgatcagccc	actgacgcgt	tgcgcgagaa	gattgtgcac	cgccgcttta	840
caggcttcga	cgccgcttcg	ttctaccatc	gacaccacca	cgctggcacc	cagttgatcg	900
gcgcgagatt	taatcgccgc	gacaattttgc	gacggcgcg	gcagggccag	actggagggtg	960
gcaacgcaa	tcagcaacga	ctgtttgccc	gccagttggt	gtgccacgcg	gttgggaatg	1020
taattcagct	ccgccatcgc	cgcttccact	ttttcccgcg	ttttcgcaga	aacgtggctg	1080
gcctgggtca	ccacgcggga	aacgggtctga	taagagacac	cggcatactc	tgcgacatcg	1140
tataacgtta	ctggtttcac	attcaccacc	ctgaattgac	tctcttcg	gcgctatcat	1200
gccataccgc	gaaagggtttt	gcaccattcg	atggtgtcgg	cagcgttggg	tcctggccac	1260
gggtgcgcat	gatcgtgctc	ctgtcgttga	ggaccgggct	agagtcgcaa	cgcaattaat	1320
gtgagttagc	tcactcatta	ggcaccaccg	gctttacact	ttatgcttcc	ggctcgtatg	1380
ttgtgtggaa	ttgtgagcgg	ataacaattt	cacacaggaa	acaggggtac	cctgcttgca	1440
aacaaaaaaa	ccaccgctac	cagcgttggt	ttgtttgccg	gatcaagagc	taccaactct	1500
ttttccgaag	gtaactggct	tcagcagagc	gcagatacca	aatactgtcc	ttctagtgtg	1560
gccgtagtta	ggccaccact	tcaagaacct	tgtagcaccg	cctacatacc	tcgctctgct	1620
aatcctgtta	ccagtggctg	ctgccagtgg	cgataagtcg	tgtcttaccg	ggttggactc	1680
aagacgatag	ttaccggata	aggcgcagcg	gtcgggctga	acgggggggtt	cgtgcacaca	1740
gcccagcttg	gagcgaacga	cctacaccga	actgagatac	ctacagcgtg	agctatgaga	1800
aagcgccacg	cttcccgaa	ggagaaaggc	ggacaggtat	ccggttaagcg	gcaggggtcgg	1860
aacaggagag	cgcacgaggg	agcttccagg	gggaaacgcc	tggtatcttt	atagtcctgt	1920
cgggtttcgc	caoctctgac	ttgagcgtcg	atttttgtga	tgctcgtcag	gggggocggag	1980

cctatggaaa	aacgccagca	acggggcctt	tttacggttc	ctggcctttt	gctggccttt	2040
tgctcacatg	ttcttttctg	cgttatcccc	tgattctgtg	gataaccgta	ttaccgcctt	2100
tgagtgagct	gataccgctc	gcgcgagccg	aacgaccgag	cgcagcgagt	cagtgagcga	2160
ggaagcggaa	gagcgcctga	tgcggtatct	tctccttacg	catctgtgcg	gtatttcaca	2220
ccgcatatgg	tgactctctc	gtacaatctg	ctctgatgcc	gcatagttaa	gccagtatac	2280
actccgctat	cgctacgtga	ctgggtcatg	gctgcgcccc	gacacccgcc	aacacccgct	2340
gacgcgccct	gacgggcttg	tctgctcccc	gcatacgcct	acagacaagc	tgtgaccgtc	2400
tccgggagct	gcatgtgtca	gaggttttca	ccgtcatcac	cgaaacgcgc	gaggcagctg	2460
cggtaaagct	catcagcgtg	gtcgtgaagc	gattcacaga	tgtctgcctg	ttcatccgcg	2520
tccagctcgt	tgagttttctc	cagaagcgtt	aatgtctggc	ttctgataaa	gcggggccatg	2580
ttaagggcgg	tttttttctg	tttggtcact	gatgcctccg	tgtaaggggg	aattctgttc	2640
atgggggtaa	tgataccgat	gaaacgagag	aggatgctca	cgatacgggt	tactgatgat	2700
gaacatgccc	ggttactgga	acgtttgtgag	ggtaaacac	tggcgggtatg	gatgcggcgg	2760
gaccagagaa	aaatcactca	gggtcaatgc	cagcgcttcg	ttaatacaga	tgtaggtgtt	2820
ccacagggtg	gccagcagca	tcctgcgatg	cagatccgga	acataatggt	gcagggcgct	2880
gacttccgcg	tttccagact	ttacgaacaa	cggaaaccga	agaccattca	tgttgttgct	2940
caggtcgcag	acgtttttgca	gcagcagtcg	cttcacgttc	gctcgcgtat	cggtgattca	3000
ttctgctaac	cagtaaggca	accccgccag	cctagatcct	tttagcttta	tgcttgtaaa	3060
ccgtttttgtg	aaaaaatttt	taaaaataaaa	aaggggacct	ctaggggtccc	caattaatta	3120
gtaataataat	ctattaaagg	tcattcaaaa	ggatcatccac	cggatccgag	ctcgaattgt	3180
aagaggttcc	aactttcacc	ataatgaaat	aagatcacta	ccgggcgtat	tttttgagtt	3240
atcgagatct	tcaggagcta	aggaagctaa	aatggagaaa	aaaatcactg	gataataccac	3300
cgttgatata	tcccaatggc	atcgtaaaga	acatttttag	gcattttcagt	cagttgctca	3360
atgtacctat	aaccagaccg	ttcagctgga	tattacggcc	tttttaaaga	ccgtaaagaa	3420
aaataagcac	aagttttatc	cggcctttat	tcacattcct	gcccgcctga	tgaatgctca	3480
tccggaattc	cgtatggcaa	tgaaagacgg	tgagctgggt	atatgggata	gtgttcaccc	3540
ttgttacacc	gttttccatg	agcaaacctga	aacgttttca	tcgctctgga	gtgaatacca	3600
cgacgatttc	cggcagtttc	tacacatata	ttcgcaagat	gtggcggtgt	acggtgaaaa	3660
cctggcctat	ttccctaaag	ggtttattga	gaatatgttt	ttcgtctcag	ccaatccctg	3720
ggtgagtttc	accagttttg	atttaaacgt	ggccaatatg	gacaacttct	tcgccccctg	3780
tttcaccatg	ggcaaatatt	atcgcaagg	cgacaagggtg	ctgatgccgc	tggcgattca	3840
ggttcatcat	gccgtctgtg	atggcttcca	tgtcggcaga	atgcttaatg	aattacaaca	3900
gtactgcgat	gagtggcagg	gcggggcgta	atttttttta	ggcagttatt	ggtgccctta	3960
aacgcctggt	gctacgcctg	aataattgat	aataagcggg	tgaatggcag	aaattcgaaa	4020
gcaaattcga	ccgggtcgtc	ggttcagggc	agggctgtta	aatagccgct	tatgtctatt	4080
gctgggttac	cggttttattg	actaccggaa	gcagtggtgac	cgtgtgcttc	tcaaatgcct	4140
gaggccagtt	tgctcaggct	ctccccgtgg	aggtaataat	tgacgatatg	atcattttatt	4200
ctgcctccca	gagcctgata	aaaacggtta	gcgcttcgtt	aatacagatg	taggtgttcc	4260
acagggtagc	cagcagcatc	ctgcgatgca	gatccggaac	ataatggtgc	agggcgcttg	4320
tttcggcggtg	ggtatggtgg	caggccccgt	ggccggggga	ctggtgggcg	ctgccggcac	4380
ctgtcctaag	agttgcatga	taaagaagac	agtcataagt	gcggcgacga	aattcagatc	4440
tgatcaagag	acagctgtcg	acgtcagggtg	gcacttttctg	gggaaatgtg	cgcggaaccc	4500
ctatttgttt	atttttctaa	atacattcaa	atatgtatcc	gctcatgaga	caataacccct	4560
gataaatgct	tcaataatat	tgaaaaagga	agagtatgag	tattcaacat	ttccgtgtcg	4620
cccttattcc	ctttttttgcg	gcatttttgc	ttcctgtttt	tgctcaoccca	gaaacgctgg	4680
tgaaagtaaa	agatgctgaa	gatcagttgg	gtgcacgagg	gagottccag	ggggaaaacgc	4740
ctggatatctt	tatagtctctg	tcgggtttctg	ccacctctga	cttgagcgtc	gattttttgtg	4800
atgctcgtca	ggggggcgga	gcctatggaa	aaacgccagc	aacgcggcct	ttttacggtt	4860
cctggccttt	tgctggcctt	ttgctcacat	gttcttttct	gcgttatccc	ctgattctgt	4920
ggataaccgt	attaccgcct	ttgagtgaac	tgataccgct	cgccgcagcc	gaacgaccga	4980
gcgcagcgag	tcagtgagcg	aggaagcgac	agctgtctct	tgatcagatc	tcatgcaagc	5040
ttcagctcac	tcactcaaga	tgtgtataag	agacagtcga	gatccccgcc	acggttgatg	5100
agagctttgt	tgtagggtga	ccagttgggtg	attttgaact	tttgcttttg	caoggaacgg	5160
tctgcgttgt	cgggaagatg	cgtgatctga	tccttcaact	cagcaaaagt	tcgattttatt	5220
caacaaagcc	gccgtcccg	caagtacg	taatgctctg	ccagtgttac	aaccaattaa	5280
ccaattctga	ttagaaaaac	tcacgagca	tcaaatgaaa	ctgcaattta	ttcatatcag	5340
gattatcaat	accatatttt	tgaaaaagcc	gtttctgtaa	tgaaggagaa	aactcaccga	5400
ggcagttcca	taggatggca	agatccctgg	atcggctctg	gattccgact	cgtccaacat	5460
caatacaacc	tattaatttc	ccctcgtcaa	aaataaggtt	atcaagtgag	aaatcaccat	5520
gagtgaacgac	tgaatccggt	gagaatggca	aaagtttatg	cattttctttc	cagacttggt	5580

caacaggcca	gccattacgc	togtcatcaa	aatcactcgc	atcaacccaa	ccgttattca	5640
ttcgtgattg	cgcttgagcg	agacgaaata	cgcgatcgct	gttaaaagga	caattacaaa	5700
caggaatcga	atgcaaccgg	cgaggaaca	ctgccagcgc	atcaacaata	ttttcacctg	5760
aatcaggata	ttctttcta	acctggaatg	ctgtttttcc	ggggatcgca	gtgggtgagta	5820
accatgcata	atcaggagta	cggataaaaat	gcttgatggg	cggaagaggc	ataaattccg	5880
tcagccagtt	tagtctgacc	atctcatctg	taacatcatt	ggcaacgcta	cctttgccat	5940
gtttcagaaa	caactctggc	gcacgaggct	tcccatataa	tcgatagatt	gtcgcacctg	6000
attgcccgcg	attatcgoga	gcccatttat	accatataa	atcagcatcc	atgttggaat	6060
ttaatcgcg	cctcgagcaa	gacgtttccc	gttgaatatg	gtcataaaca	ccccttgat	6120
tactgtttat	gtaagcagac	agttttattg	ttcatgatga	tatatTTTTA	tcttgtgcaa	6180
tgtaacatca	gagattttga	gacacaacgt	ggctttcccc	ccccccccta	tgccgtgtga	6240
aataccgcac	agatgcgtaa	ggagaaaata	ccgcatcagg	acgcgccctg	tagcggcgca	6300
ttaaagcgcg	cggtgtgtgt	ggttacgcgc	agcgtgacgc	tacacttgcc	agcgccctag	6360
cgcccgctcc	tttcgctttc	ttcccttcc	ttctcgccac	gttcgccatg	cataatgtgc	6420
ctgtcaaatg	gacgaagcag	ggattctgca	aaccctatgc	tactccgtca	agccgtcaat	6480
tgtctgattc	gttaccaatt	atgacaactt	gacggctaca	tcattcactt	tttcttcaca	6540
accggcacgg	aactcgctcg	ggctggcccc	gggtgcatTTT	ttaaataccc	gcgagaaaata	6600
gagttgatcg	tcaaaaccaa	cattgcgacc	gacggtggcg	ataggcatcc	gggtgggtgct	6660
caaaagcagc	ttcgccctgg	tgatacgttg	gtccctcgcg	cagcttaaga	cgctaattccc	6720
taactgctgg	cgaaaaagat	gtgacagacg	cgacggcgac	aagcaaacat	gctgtgcgac	6780
gctggcgata	tcaaaattgc	tgtctgccag	gtgatcgctg	atgtactgac	aagcctcgcg	6840
tacccgatta	tccatcggtg	gatggagcga	ctcgtaaatc	gcttccatgc	gccgcagtaa	6900
caattgctca	agcagattta	tcgccagcag	ctccgaatag	cgcccttccc	cttgcccggc	6960
gttaatgatt	tgcccaaaca	ggtcgctgaa	atgcggctgg	tgcgcttcat	ccgggagaaa	7020
gaaccccgta	ttggcaaata	ttgacggcca	gttaagccat	tcatgccagt	aggcgcgcg	7080
acgaaagtaa	acccactggg	gataccattc	gcgagcctcc	ggatgacgac	cgtagtgatg	7140
aatctctcct	ggcggaaca	gcaaaatatc	accggtcg	caaacaatt	ctcgccctg	7200
atttttcacc	acccctgac	cgcgaatggg	gagattgaga	atataacctt	tcattcccag	7260
cggtcggtcg	ataaaaaaat	cgagataacc	gttggcctca	atcggcgtta	aacccgccac	7320
cagatgggca	ttaaacgagt	atcccggcag	caggggatca	ttttgcgctt	cagccatact	7380
tttcatactc	ccgccattca	gagaagaaac	caattgtcca	tattgcatca	gacattgcg	7440
tcactgcgtc	ttttactggc	tcttctcgct	aaccaaaaccg	gtaaccccg	ttattaaaag	7500
cattctgtaa	caaagcgga	ccaaagccat	gacaaaaacg	cgtaacaaaa	gtgtctataa	7560
tcacggcaga	aaagtccaca	ttgattattt	gcacggcgctc	acactttgct	atgccatagc	7620
atttttatcc	ataagattag	cggatccctt	ctgacgcttt	ttatcgcaac	tctctactgt	7680
ttctccatac	ccgttttttt	gggctagaaa	taattttggt	taactttaag	aaggagatat	7740
aacctgata	acttctgctc	ttcatcgctg	ggccgactgg	gctaaatctg	tggtctcttc	7800
ggcggcgctg	ggtgatcctc	gccgtactgc	ccgcttggtt	aacgtcgccg	cccaattggc	7860
aaaatattct	ggtaaatcaa	taacctctc	atcagagggt	agtaaagccg	cccaggaagg	7920
cgcttaccga	tttatccgca	atcccaacgt	ttctgcccag	gcgatcagaa	aggctggcgc	7980
catgcaaaaa	gtcaagttgg	ctcaggaggt	tcccgaactg	ctggccattg	aggacaccac	8040
ctctttgagt	tatcgccacc	aggctcgccga	agagcttggc	aagctgggct	ctattcagga	8100
taaatcccgc	ggatggtggg	ttcaactcgt	tctcttgctc	gaggccacca	cattccgcac	8160
cgtaggatta	ctgcatcagg	agtgggtggg	gcgcccggat	gaccctgccg	atgcggatga	8220
aaaggagagt	ggcaaatggc	tggcagcggc	cgcaactagc	cggttacgca	tgggcagcat	8280
gatgagcaac	gtgattgogg	tctgtgaccg	cgaagccgat	attcatgctt	atctgcagga	8340
caaactggcg	cataacgagc	gcttcgtggg	gcgctccaag	caccacgca	aggacgtaga	8400
gtctgggttg	tatctgtacg	accatctgaa	gaaccaaccg	gagttgggtg	gctatcagat	8460
cagcattccg	caaaaggggc	tgggtggataa	acgcggtaaa	cgtaaaaaatc	gaccagccc	8520
caaggcgagc	ttgagcctgc	gcagtgggcg	catcacgcta	aaacagggga	atatcacgct	8580
caacgcggtg	ctggccgagg	agattaaccc	gcccgaagggt	gagaccccgt	tgaaatgggt	8640
gttgctgacc	agcgaaccgg	tcgagtcgct	agcccaagcc	ttgcgcgtca	tcgacattta	8700
tacccatcgc	tggcggatcg	aggagtcca	taaggcatgg	aaaaccggag	caggagccga	8760
gaggcaacgc	atggaggagc	cggataatct	ggagcggatg	gtctcgatcc	tctcgttgt	8820
tgccgtcagg	ctgttacagc	tcagagaaaag	cttcacgccc	ccgcaagcac	tcaggggcgca	8880
agggctgcta	aagggaagcg	aacacgtaga	aagccagtcc	gcagaaacgg	tgctgacccc	8940
ggatgaatgt	cagctactgg	gctatctgga	caagggaata	cgcaagcgca	aagagaaagc	9000
aggtagcttg	cagtgggctt	acatggcgat	agctagactg	ggcggtttta	tggacagcaa	9060
gcgaaccgga	attgccagct	ggggcgccct	ctggtaaggt	tgggaagccc	tgcaaaagtaa	9120
actggatggc	tttcttgccg	ccaaggatct	gatggcgacg	gggatcaaga	tctgatccgg	9180

```
gctttccccc tcaagctcta aatcgggggc tcgactgtct cttatacaca tcttgagtga 9240
gtgagaacct gcattaatga atcgg                                     9265
```

QBMAD\319926.1